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3 Abstract 
Toll-like receptor (TLR) ligands may be employed as adjuvants for allergen-specific 
immunotherapy. For example, CpG motifs recognized by TLR9 were shown to promote the 
counter regulation of the allergic immune response when added to allergy vaccines. We were 
interested to investigate whether the bacterial protein flagellin, a TLR5 ligand, excerted 
immunomodulating effects on cells of allergic patients and to produce flagellin in 
recombinant form. 
As a first step, we stimulated peripheral blood mononuclear cells (PBMC) from birch pollen-
allergic patients with commercially available flagellin from Salmonella typhimurium and 
analysed cytokine expression by ELISA. The induction of IFN-γ and IL-10 indicated that 
flagellin had potential adjuvant activity. Next, we established a read out system to detect 
TLR5-triggering using human embryonic kidney (HEK) cells stably transfected with TLR5 as 
well as CaCo-2 cells. In parallel, we assessed the influence of heat-labile serological factors 
on the ability of flagellin to activate TLR5. Our results indicated that HEK-293/TLR5 cells in 
the presence of FCS (10%) were best suited for testing TLR5 triggering by flagellin. 
Next we tried to clone flagellin from S. typhimurium in a suitable vector and express the 
protein in E. coli BL21(DE3)pLysS cells. As different attempts to produce recombinant 
flagellin failed, we focussed on the expression of the C- and N-terminal fragments of the 
protein. These conserved regions form the D0 and D1 domain of flagellin responsible for 
recognition by TLR5. Both protein fragments were successfully expressed in E. coli 
BL21(DE3)pLysS cells and purified by chromatography. However, neither a mixture nor the 
C- and N-terminal fragments alone bound to TLR5. Therefore, we designed a fusion protein 
linking both fragments with a hinge region from E. coli. This fusion protein was expressed, 
purified by chromatography and tested on HEK-293/TLR5 cells. Stimulation of the cell line 
with the fusion protein led to IL-8 synthesis revealing that the N- and C-terminal fragments 
need to be brought into close proximity to bind and activate TLR5. 
In summary, we showed that flagellin may have immunomodulatory effects on cells of 
allergic patients. Moreover, we established a test system for TLR5 triggering and produced a 
recombinant fusion protein consisting of the highly conserved N- and C-terminal fragments of 
flagellin from S. typhimurium linked by a hinge region from E. coli with the capacity to 
trigger TLR5. 
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In the future, it is planned to produce sufficient amounts of the recombinant fusion protein in 
high purity and free of endotoxins to evaluate its immunomodulatory effects on PBMC of 
allergic donors. 
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4 Aims of the study 
 
In this diploma thesis we aimed at 
 
 
• evaluating whether flagellin from S. typhimurium could induce TH1/Treg-type 
cytokines and therefore, was a potential adjuvant in allergen-specific immunotherapy. 
 
 
• establishing a fast read-out system for TLR5 triggering. 
 
 
• cloning and expressing of flagellin from S. typhimurium in E. coli cells. 
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5 Introduction 
5.1 Immune system 
The human immune system offers various defence mechanisms against infections by 
pathogens or pathogen-derived products. One can generally differentiate between an 
evolutionary elder innate immune system and a younger adaptive immune system. The innate 
or natural immune system constitutes physical and chemical barriers like epithelia, 
membranes and various cell types such as neutrophils, NK-cells and especially macrophages, 
which are very important in the first-line defence against pathogens. Typically, the innate 
immune system recognizes structures shared by many classes of microbes using so-called 
pattern recognition receptors (PRR). However, the components of the innate immune system 
are germline encoded and therefore, this system possesses a limited diversity and does not 
produce immunological memory. In contrast, the adaptive immune system offers a large 
diversity and the ability to produce immunological memory. The adaptive immune system 
either acts by humoral components or by lymphocytes. There are two major subclasses of 
lymphocytes involved in antigen recognition and removal: B- and T-lymphocytes. According 
to the type of antigen receptor they express, T-lymphocytes are further differentiated into αβ-
T-lymphocytes and γδ-T-lymphocytes. The T-cell receptor consists of two transmembrane 
polypeptide chains named α and β or γ and δ, respectively. The single chains are covalently 
linked to each other by disulfide bridges and therefore, form the heterodimeric receptor. The 
αβ-T-lymphocytes are much more frequent. Less than 5% of all T-cells express the γδ-T-cell 
receptor with variations in different tissues. Mature αβ-T-cells are classified in CD4+ or CD8+ 
T-cells according to the co-receptor molecules they express. The CD8+ subset is usually 
called cytotoxic T-lymphocytes (TC) as they are responsible for direct killing of infected cells 
after infection with microbes that replicate intracellularly. CD4+ T-cells are generally known 
as helper T-cells (TH) as they help in activating phagocytes after ingestion of microbes or 
mediate B-lymphocyte activation. In addition regulatory CD4+ T-cells exist, that have 
important functions in the regulation of immune responses and in the maintenance of self-
tolerance as they suppress the function of other T-cells. These mechanisms help the immune 
system to downregulate responses after infections and to keep a balance between pro- and 
anti-inflammatory immune responses. 
B-lymphocytes produce antibodies (immunoglobulins). In humans there exist 5 
immunoglobulin isotypes named IgM, IgG, IgA, IgE and IgD. 
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The main role of the innate and the adaptive immune system is to ensure the defence against 
all types of different pathogens. Unfortunately, sometimes autoimmune reactions or 
hypersensitivity reactions occur [1]. According to Coombs and Gell, hypersensitivity 
reactions of the human immune system are classified into 4 different types. However, today it 
is discussed whether this classification system summarizes all types of hypersensitivity 
reactions or whether additional types exist [2, 3]. Type 1 hypersensitivity reactions are based 
on IgE-mediated degranulation of sensitized basophils and mast-cells. Allergic asthma or 
rhinoconjunctivitis are examples for Type 1 hypersensitivity reactions. Type 2 
hypersensitivity reactions result from the interaction of IgG or IgM antibodies with cell bound 
antigens. Antigen-antibody binding leads to the local production of  anaphylatoxin (C5a) and 
subsequent tissue injury by the release of hydrolytic neutrophil enzymes [2]. Type 3 
hypersensitivity reactions are so-called immune complex reactions. Antigen-Antibody 
complexes are formed and deposited in the glomerular or pulmonary basement membranes 
causing tissue injury [2]. Finally, there are cell-mediated reactions or Type 4 hypersensitivity 
reactions. They are mediated by T-cells, macrophages, natural killer cells or other leukocytes 
[2]. 
 
5.2 Type 1 allergy 
The elicitors of Type 1 hypersensitivity reactions are harmless antigens, so-called allergens. 
Allergens usually are proteins of a molecular weight of 5-100 kDa that can be categorized into 
different protein families according to their structure [4]. Allergens are frequently 
glycosylated and easily soluble in body fluids. Some allergens also show protease activity [5]. 
Common sources of allergens include pollen, mite feces, insect venom or different foods. In 
industrialized countries the most prominent allergen sources are feces from house-dust mite, 
pollen from grasses and trees and epithelia from cat [6]. 
The development of Type 1 allergy is a two step process. At first, sensitization to allergens 
occurs, which is followed by a reaction phase that can be subdivided into an early and a late 
phase. At first contact, allergens are taken up by antigen presenting cells (APC) that migrate 
to the draining lymph nodes. After processing of the allergen by the APC, allergen-derived 
peptides are bound to major histocompatibility complex (MHC) molecules. Upon contact with 
the APC, naïve T-cells differentiate into different effector cells depending on key cytokines in 
their environment. CD4+ T–cells are today subdivided into TH1 cells, TH2 cells, TH17 cells 
and Treg regulatory cells according to the cytokine pattern produced by these cells. Type 1 
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allergy is characterized by an overwhelming TH2 response to allergens. Atopic patients are 
prone to develop TH2-like immune reactions whereas non-allergic patients more often show a 
TH2/TH1/Treg balanced immune response to allergens [6]. TH2 cells secrete cytokines like 
interleukin-4 (IL-4), IL-5 and IL-13 whereas interferon-γ (IFN-γ) is the major product of TH1 
cells. Under the influence of IL-4 and CD40 ligand, B-cells undergo isotype switching to IgE 
production. IgE antibodies circulating in the blood are bound to the high-affinity receptor for 
IgE (FcεRI) expressed on the surface of basophils and mast cells, which renders these effector 
cells “sensitized”. Upon any consecutive allergen encounter, bound IgE antibodies recognize 
and bind the allergen resulting in cross-linking of IgE molecules and mast cell activation. This 
reaction phase can be divided into early phase and late phase reactions. Cross-linking of the 
FcεRI molecules starts a typical signalling cascade resulting in immediate clinical symptoms 
due to the release of preformed granule contents, synthesis of lipid mediators and also 
cytokine production. Mediators such as histamine, prostaglandin D2 or platelet-activating 
factor cause increased vascular permeability and stimulation of smooth muscle cell 
contraction as well as vasodilation and bronchoconstriction. Cytokine production and newly 
synthesized mediators cause the late phase reactions and inflammation [7]. Symptoms of 
allergic diseases can range from allergic rhinitis to asthma, atopic dermatitis or anaphylactic 
shock, which is a perilous situation. 
 
Type 1 allergy has become a major threat for public health as up to 20% of adults in 
industrialized countries develop IgE-mediated or Type 1 hypersensitivity reactions. 
The “hygiene hypothesis” tries to provide an explanation for the high occurrence of allergic 
disorders in industrialized countries [8]. The stimulation of the immune system by microbial 
compounds in early life may have a protective effect on the development of allergy. Maybe 
the IL-12 rich environment resulting from permanent stimulation with microbes is important 
to develop TH1-like immune responses. Children in industrialized countries often lack the 
exposure to pathogens because they grow up in high sanitary standards. Therefore, these 
children often develop TH2-biased immune responses as the development of the TH1-like arm 
is reduced. Studies showing a protective effect on the development of allergic disorders for 
children that grew up on a farm support this theory [9, 10]. Still, allergic disorders are 
multifactorial and often have a genetic background. Therefore, family history may be used as 
a predictor of asthma risk and atopy. Growing up with siblings also seems to decrease chances 
of developing Type 1 allergies as children who have three or more older siblings develop 
allergic diseases less frequent as compared to single children [11]. Again, this may be 
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explained by the exposure to pathogens as elder siblings frequently have contact with other 
children e.g. in school and therefore, also with a variety of pathogens. However, recent data 
have excluded a protective effect of the number of siblings and rather support an in-utero 
programming hypothesis [11, 12]. 
The influence of environmental factors on the development of allergies is also considerable. 
Air pollutants were shown to induce an increased release of allergens from pollen and to lead 
to class switch towards IgE in nasal epithelia [13, 14]. Nevertheless, the development of 
allergies strongly depends on the genetic background of an individual. Allergic individuals are 
frequently atopic, i.e. they show a tendency to produce IgE antibodies. IgE levels in plasma of 
non-allergic patients are normally less than 1µg/mL but can rise up to 1000 µg/mL in atopic 
patients. In addition several gene loci have been shown to correlate with allergy development 
such as a polymorphism in the gene for the β-chain of the high-affinity receptor for IgE [15]. 
 
5.3 Allergen-specific immunotherapy 
The aim of allergen-specific immunotherapy (SIT) is to generate long-term clinical tolerance 
to natural allergen exposure. To date, SIT is the only causative treatment for Type 1 allergy. 
Conventional SIT is based on repeated subcutaneous injections of increasing doses of allergen 
over a long time-period. Other application routes have been tested and sublingual allergen-
specific immunotherapy (SLIT) is considered as an alternative because it is safe, non-invasive 
and more convenient for the patient [16]. Successful SIT/SLIT has been associated with the 
downregulation of the allergen-specific TH2-like immune response by inducing IFN-γ-
producing TH1 cells and the shift towards a more physiologic TH0/TH1-like response [17]. 
Additionally, SIT/SLIT induces IL-10- or transforming growth factor β (TGF-β)-producing 
regulatory T-cells (Treg) that actively suppress allergen-specific T-cell responses [18-20]. IFN-
γ and IL-10 also favour the production of allergen-specific IgG antibodies which can function 
as blocking antibodies and compete with IgE for allergen binding [21, 22]. Consequently, the 
typical signalling pathways leading to allergic symptoms and immediate hypersensitivity 
reactions are reduced. 
The administration of allergens to the patient bears a risk for IgE-mediated side effects in SIT. 
Therefore, improvement of allergen-specific immunotherapy is very important. Injection SIT 
has been improved by the use of recombinant allergens instead of crude allergen extracts [23]. 
Vaccination with recombinant allergens that were genetically modified to reduce their IgE-
binding capacity was shown to prevent progression of allergic disease [24]. 
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Another approach to improve the efficacy of SIT is the use of adjuvants that support the 
development of TH0/TH1-like immune responses to allergens. This can be achieved by 
targeting the innate immune response, e.g. activation of Toll-like receptors (TLR). Different 
TLR agonists have been shown to be promising adjuvant candidates in allergy vaccines as 
they induce regulatory T-cells and TH1-type immune responses [25]. These approaches were 
further supported by first positive results in clinical trials and TLR agonists are considered as 
important in supporting the efficacy of SIT [26]. 
 
5.4 Toll-like receptors 
TLR are members of the pattern recognition receptor family and are expressed on different 
cell types but mainly on cells of the innate immune system such as dendritic cells (DC), 
macrophages and endothelial cells. They are responsible for recognition of pathogen-
associated molecular patterns (PAMP). TLR were named after Toll, a gene that is responsible 
for establishment of dorsal-ventral orientation in Drosophila melanogaster and has later been 
shown to also mediate antifungal responses [27, 28]. To date, the TLR family consists of 11 
members in humans and 13 members in mice [29]. All of them are type 1 membrane proteins 
and have characteristic ectodomains consisting of leucine rich repeats (LRR) by which PAMP 
of different origin can be recognized. Several TLR including TLR1, TLR2, TLR4, TLR5, 
TLR6 and TLR10 are expressed on the cell surface. In contrast, TLR3, TLR7, TLR8 and 
TLR9 are localized in intracellular compartments. Besides division by cellular localization, 
TLR can also be categorized according to the type of PAMP they recognize. TLR1, TLR2, 
TLR4 and TLR6 are required for recognition of lipids. TLR3, TLR7, TLR8 and TLR9 
recognize nucleic acids and TLR5 as well as TLR11 are required for recognition of proteins 
[29]. After recognition, signalling starts via the cytoplasmic domain, which is called Toll/IL-1 
receptor (TIR) homology domain. Adapter proteins are recruited leading to activation of 
protein kinases resulting in activation of transcription factors. Finally, genes are transcribed 
for expression of inflammatory cytokines such as IL-12 and TNF-α but also for up-regulation 
of co-stimulatory molecules, e.g. CD80 or CD86. Together, all of these factors support DC 
maturation and TH1 differentiation [29]. Apart from that, TLRs also play a role in the 
induction of immunological tolerance [30]. 
TLR ligands trigger innate as well as adaptive immune responses by activating the TLR 
signalling cascades. As already mentioned, some TLR ligands can be considered as potential 
adjuvants for SIT as they support the shift from a TH2 type to a TH0/TH1 type response in 
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allergic individuals. For Type 1 allergies, clinical trials with TLR4 and TLR9 ligands have 
already shown promising results [26, 31]. 
 
5.5 Flagellin 
Flagellin is a TLR5 ligand and the monomeric subunit of flagella carried by several Gram-
positive and Gram-negative bacteria. Flagella are whip-like structures that are up to 15 µm 
long with a diameter of around 20 nm and composed of many flagellin monomers [32]. 
Flagella are characterized by a basal body anchored in the inner and outer cell membrane that 
uses the proton motive force for motor function [33]. Furthermore, there is a torsion hook 
conferring flexibility to the relatively stiff flagellum, which is a helical filament. Flagella 
confer bacterial motility either by running, where the flagellar filament rotates 
counterclockwise, or by tumbling, where motor rotation is quickly changed to a clockwise 
direction. Flagella can also increase the adhesive potential of pathogenic bacteria, e.g. in 
colonization of the gut, or they serve as Type 3 secretion systems (TTSS) to secrete virulence 
factors. 
Transcription of the flagellar genes is controlled via the flhDC regulator operon [33]. 
The flagellar filament is composed of about 30000 flagellin subunits, each consisting of 4 
domains (Fig.1). Assembly of the flagellum is achieved by export of the flagellin subunits 
through the bacterial membrane by a Type 3 secretion like system. After export the flagellin 
subunits are polymerized, a process that is promoted by a capping structure at the end of the 
filament (Fig.1). To date more than 200 different flagellin sequences are known and sequence 
analysis has revealed that flagellin mRNA is highly conserved amongst different bacterial 
species with regard to the N- and the C-terminus of the protein. In contrast, the central region 
of the protein varies strongly in different species [33, 34]. The conserved regions are mainly 
responsible for the formation of the D0 and D1 domains that are characterized by their α-
helical structure and are recognized by the innate immune system. The D2 and D3 domains 
contain β-sheets, formed mainly by the variable central region, and protrude from the compact 
chain that is formed by the D0 and D1 domains. Therefore, adaptive immune responses like 
recognition of flagellin by antibodies are mostly directed against the variable regions. 
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Figure 1: Schematic overview of a flagellin subunit and the flagellar assembly 
 
Recognition of flagellin is accomplished by TLR5 binding to conserved amino acid residues 
in the D1 domain of flagellin. Binding of flagellin by TLR5 leads to receptor dimerization 
followed by the recruitment of MyD88 and activation of a typical signalling cascade [35, 36]. 
Flagellin monomers were demonstrated to be much more potent in eliciting TLR5 activity as 
compared to filamentous flagella [37].  
TLR5 is expressed by monocytes, immature dendritic cells (DC) and also by epithelial cells 
[35]. TLR5 is also expressed in neutrophils and evidence has been provided that the receptor 
is recruited to the phagosome upon ligand-driven activation in phagocytic cells [38]. A recent 
study showed that pancreatic stellate cells expressed TLR5 and responded to flagellin from 
Salmonella münchen [39]. 
 
In this diploma thesis we wanted to clone and express the TLR5 ligand flagellin from 
Salmonella typhimurium and then further characterize the recombinant protein with regard to 
its biological function. Salmonella belong to the class of γ-proteobacteria. The family name is 
enterobacteria and Salmonella typhimurium is one serovar of the diverse genus of Salmonella 
enterica. Some Salmonella species including S. typhimurium are pathogenic for animals or 
humans and Salmonella infections (called salmonellosis) can even be lethal. According to the 
WHO salmonellosis affects millions of humans every year. This food-bourne disease causes 
symptoms like diarrhea, abdominal cramps and fever within the first 12 to 72 hours after 
infection and usually lasts up to 7 days. Salmonellosis is normally not lethal and does not 
require medical treatment but it may get problematic for immunocomprimised or elder people 
and children. 
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6 Materials and methods 
6.1 Tissue culture 
6.1.1 Isolation of peripheral blood mononuclear cells (PBMC) 
Peripheral blood mononuclear cells were isolated from heparinized human blood as follows: 
1) Dilute blood 1:2 with 1x DPBS (Gibco®, Invitrogen GmbH, Haus 223, Lofer, 
Austria). 
2) Overlay 15 mL of Ficoll solution with approximately 35 mL of diluted blood. 
3) Centrifuge at 22°C at 399x g for 30 minutes (stop without brake). 
4) Carefully collect the plasma (upper phase) without harming the interphase. Plasma can 
be frozen at -20°C. 
5) Pipet the PBMC-interphase and residual plasma into a fresh 50 mL tube. Avoid uptake 
of Ficoll solution and pool 2 interphases per tube. Fill up to 50 mL with 1x DPBS. 
6) Centrifuge at 885x g at 22°C for 10 minutes and maximal brake. Discard supernatant 
directly and resuspend the pellet in 5 mL of 1x DPBS. 
7) Pool 2 resuspended pellets in one tube and fill up to 50 mL with 1x DPBS. 
8) Centrifuge at 737x g at 22°C for 10 minutes and maximal brake. Decant supernatant 
and resuspend the pellet in 5 mL of 1x DPBS. Pool resuspended cells in one 50 mL 
tube and fill up to 50 mL with 1x DPBS. 
9) Count cells using a Bürker-Türk counting chamber (LO Laboroptik GmbH, 
Friedrichsdorf, Germany). Check viability by mixing 10 µL of the cell suspension 
with 10 µL of Trypane blue solution. Count 100 cells and calculate the percentage of 
living cells appearing white in the microscope compared to dead cells appearing as 
blue. 
6.1.2 Thawing of frozen human embryonic kidney (HEK) or CaCo-2 cells 
One aliquot of cells (8x106 cells) was taken out of the liquid nitrogen tank and for pressure 
compensation the cap was slightly opened and closed again immediately. Thereafter, the 
aliquot was thawed at 37°C in the waterbath. Cells were transferred into a Sterilin tube 
containing fresh 1x PBS and the cryo-tube was also washed with 1x PBS. Thereafter, the cell 
suspension was centrifuged for 8 minutes at 737x g at 22°C in a Beckman Coulter Allegra™ 
X-12R centrifuge (Beckman Coulter GmbH, Krefeld, Germany). The supernatant was 
discarded. The pellet was resuspended in 5 mL of fresh cell culture medium and this cell 
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suspension was transferred into a 25 cm² cell culture flask and incubated at 37°C in 
humidified atmosphere containing 5% CO2. The next day the used medium was discarded and 
replaced by fresh, pre-warmed medium. Viability was checked using the microscope. 
6.1.3 Culturing of HEK or CaCo-2 cells 
Cells were grown to a confluent stage and thereafter, the used medium was discarded. Cells 
were washed with pre-warmed 1x PBS and Trypsin/EDTA solution was added. Cells were 
detached by panning the cell culture flask gently. If cells did not detach well the cell culture 
flask was incubated at 37°C for a few minutes. Detached cells were taken up in 5 mL of pre-
warmed medium. The flask was washed once with 5mL of medium. All cells were 
centrifuged for 8 minutes at 737x g at 22°C in a Beckman Coulter Allegra™ X-12R centrifuge 
(Beckman Coulter GmbH). The supernatant was discarded and the cell pellet was resuspended 
in 5 mL of fresh medium. An aliquot of 0.5 mL to 2.5 mL was taken out of the cell suspension 
and transferred back into the cell culture flask to divide cells by 1:10 or 1:2, respectively. 
Thereafter, fresh medium was added and the cell culture flask was incubated at 37°C in 
humidified atmosphere containing 5% CO2. 
6.1.4 Creating frozen stocks of HEK or CaCo-2 cells 
To generate frozen stocks of HEK or CaCo-2 cell lines, cells were detached using 
Trypsin/EDTA as described above and centrifuged for 8 minutes at 737x g at 22°C in a 
Beckman Coulter Allegra™ X-12R centrifuge (Beckman Coulter GmbH). The supernatant 
was discarded and cells were resuspended in 10 mL of fresh medium. Cell numbers and 
viability were determined by counting cells in a Bürker Türk counting chamber (LO 
Laboroptik GmbH, Friedrichsdorf, Germany). Cells were centrifuged at 737x g at 22°C. All 
further steps were done on ice. The supernatant was discarded and the cell pellet was 
resuspended in N2 medium to reach a final concentration of 8x10
6 cells per mL. Aliquots of 1 
mL of the cell suspension were pipetted into cryo-tubes and immediately frozen at -80°C for 
at least 12 hours. Thereafter, the cryo-tubes were transferred into a liquid nitrogen tank. 
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6.1.5 Stimulation of PBMC 
All stimuli were diluted in UCФ medium (Lonza Ultra culture medium supplemented with 
Glutamine, β-mercaptoethanole and Gentamycin) and 100 µL/well were added to 
flatbottomed 96 well plates (Corning B.V. Life Sciences, Schiphol-Rijk, The Netherlands). If 
polymyxin treatment was necessary, the stimuli were pre-incubated with polymyxin (Sigma-
Aldrich Handels GmbH; 20 µg/mL final concentration) at 37°C for 30 minutes. PBMC (500 
000 cells/well) were seeded in 100 µL of UCФ medium per well. Supernatants were harvested 
after 48 hours of incubation at 37°C in humidified atmosphere containing 5% CO2 and 
cytokine levels were assessed by ELISA. 
6.1.6 Stimulation of HEK or CaCo-2 cells 
HEK cells stably transfected with TLR5 or CaCo-2 cells (40000 cells/well) were seeded into 
flatbottomed 96 well plates (Corning B.V. Life Sciences) in a volume of 100 µL/well in the 
respective culture medium. Plates were incubated at 37°C in humidified atmosphere 
containing 5% CO2 for 24 hours to let the cells grow confluently. Medium was removed 
carefully to avoid loss of any cells and 100 µL/well of fresh medium containing the specific 
stimuli were added. 
Supernatants were collected after 20 h of incubation at 37°C in a humidified atmosphere 
containing 5% CO2. 
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6.1.7 Cytokine ELISA 
The levels of different cytokines after stimulation of either HEK or CaCo-2 cells or PBMC 
were determined by ELISA. Nunc Maxisorb 96 well plates (Thermo Scientific Inc., Rockford, 
USA) were coated with the respective coating antibodies diluted in carbonate buffer (pH = 
9.6) in a final volume of 100 µL/well and incubated O/N at RT. The next day, the coating 
antibodies were removed and 150 µL of PBS/0.05% (v/v) Tween20/4% (w/v) BSA were 
added per well and incubated for 60 minutes at RT as blocking solution. 
Thereafter, plates were washed 3 times using 200 µL of PBS/0.05% Tween20 (v/v). 
Standards and samples were diluted in PBS/0.05% (v/v) Tween20/4% (w/v) BSA, pipetted on 
the plates in a volume of 50 µL/well and incubated at RT for 60 minutes. They were discarded 
and the Biotinlyated antibodies diluted in PBS/0.05% (v/v) Tween20/4% (w/v) BSA were 
added to the plates in a volume of 50 µL/well and incubated at RT for 60 minutes. Plates were 
washed 3 times using 200 µL of PBS/0.05% (v/v) Tween20. Thereafter, HRP conjugated 
streptavidin (1.25 mg/mL) was added in a dilution of 1:20000 (diluted in PBS/0.05% (v/v) 
Tween20/4% (w/v) BSA) and incubated for 30 minutes at RT. 
After washing with 200 µL of PBS/0.05% (v/v) Tween20 three times, 100 µL/well of TMB/E 
solution (Chemicon International Inc, Billerica, USA) were added and incubated for 30 
minutes in the dark at RT. Finally, the reaction was stopped by adding 0.18 M H2SO4 (100 
µL/well) and the absorbance was measured at 450 nm (reading) and 630 nm (reference) using 
a Spectra max Plus 384 plate reader (Molecular Devices, Sunnyvale, USA) and the SOFTmax 
Pro 4.8 software. 
Antibody Cytokine ELISA 
 IL-8 IL-10 IFN-γ TNF-α 
Coating  Endogen M801 
(2 µg/mL) 
Endogen M010 
Isotype: Rat IgG1 
(1 µg/mL) 
Calbiochem Anti γ-
IFN mouse mAb 
(0.5 µg/mL) 
Endogen M303 
(2 µg/mL) 
Standard Endogen S-IL8 
(500 pg/mL) 
Endogen S-IL10  
(500 pg/mL) 
Endogen S-IFNγ 
(500 pg/mL) 
Endogen S-TNF-α  
(500 pg/mL) 
Biotinylated  Endogen M802B 
(0.2 µg/mL) 
Endogen M011B 
(1 µg/mL) 
Endogen M701B  
(2 µg/mL) 
Endogen M302B 
(0.9 µg/mL) 
 
 
 19 
6.2 Cloning 
6.2.1 Purification of total DNA from Gram negative bacteria 
Total DNA from Gram negative bacteria was purified using the QIAGEN DNeasy blood and 
tissue kit (QIAGEN, Hilden, Germany) following the manufacturer’s instructions. All 
centrifugation steps were performed in an Eppendorf 5417C tabletop centrifuge (Eppendorf 
AG, Hamburg, Germany). 
Procedure: 
1) Harvest cells (maximum 2x109 cells) in a microcentrifuge tube by centrifuging for 10 
min at 7500 rpm. Discard the supernatant. 
2) Resuspend pellet in 180 µL of Buffer ATL. 
3) Add 20 µL of proteinase K. Mix thoroughly by vortexing and incubate at 56°C until 
the cells are completely lysed. Vortex occasionally during incubation to disperse the sample. 
4) Vortex for 15 s. Add 200 µL of Buffer AL to the sample and mix thoroughly by 
vortexing. Then add 200 µL of ethanol (96-100%) and mix again thoroughly by vortexing. 
5) Pipet the mixture from step 4 (including any precipitate) into the DNeasy Mini spin 
column placed in a 2 mL collection tube. Centrifuge at 8000 rpm for 1 min. Discard flow-
through and collection tube. 
6) Place the DNeasy Mini spin column in a new 2 mL collection tube, add 500 µL of 
buffer AW1 and centrifuge for 1 min at 8000 rpm. Discard flow-through and collection tube. 
7) Place the DNeasy Mini spin column in a new 2 mL collection tube, add 500 µL of 
Buffer AW2 and centrifuge for 3 min at 14000 rpm to dry the DNeasy membrane. Discard 
flow-through and collection tube. 
8) Place the DNeasy Mini spin column in a clean 1.5 mL microcentrifuge tube and pipet 
200 µL of Buffer AE directly onto the DNeasy membrane. Incubate at room temperature for 1 
min, then centrifuge for 1 min at 8000 rpm to elute the DNA from the column. 
9) For maximum DNA yield, repeat elution once as described in step 8. 
Step 9 was performed in a fresh 1.5 mL microcentrifuge tube. 
Eluted DNA was analysed by agarose gel electrophoresis and stored at 4°C for short time 
periods or was frozen at -20°C for longer time periods. 
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6.2.2 Plasmid preparation using the QIAprep Spin Miniprep Kit 
The QIAprep Spin Miniprep Kit (QIAGEN) was used for plasmid preparations following the 
manufacturer’s instructions. All centrifugation steps were performed in an Eppendorf 5417C 
tabletop centrifuge (Eppendorf AG). 
 
Procedure: 
1.) After centrifugation at 8000 rpm for 3 minutes resuspend pelleted bacterial cells in 
250 µL of Buffer P1 and transfer to a microcentrifuge tube. 
2.) Add 250 µL of Buffer P2 and mix thoroughly by inverting the tube 4-6 times. 
3.) Add 350 µL of Buffer N3 and mix immediately and thoroughly by inverting the tube 
4-6 times. 
4.) Centrifuge for 10 min at 13000 rpm in a table-top microcentrifuge. 
5.) Transfer the supernatants from step 4 to the QIAprep spin column by decanting or 
pipetting. 
6.) Centrifuge for 30-60 s. Discard the flow-through. 
7.) Wash the QIAprep spin column by adding 0.5 mL Buffer PB and centrifuging for 30-
60 s. Discard the flow-through. 
8.) Wash QIAprep spin column by adding 0.75 mL Buffer PE and centrifuging for 30-60 
s. 
9.) Discard the flow-through, and centrifuge for an additional 1 min to remove residual 
wash buffer. 
10.) Place the QIAprep column in a clean 1.5 mL microcentrifuge tube. To elute DNA, add 50 
µL Buffer EB (10 mM Tris-CL, pH 8.5) or water to the center of each QIAprep spin column, 
leave it for 1 min, and centrifuge for 1 min. 
In order to increase the concentration of the eluted DNA, the final elution step was done using 
35 µL of Buffer EB. 
DNA concentration was measured by spectrophotometry with a Hitachi U-1800 
spectrophotometer (Hitachi High Technologies, Berkshire, UK) at 260 nm and 280 nm and 
plasmid DNA was stored at -20°C. 
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6.2.3 Preparation of frozen bacterial stocks 
To generate frozen bacterial stocks for long term storage, 800 µL of an overnight culture of 
bacterial cells were transferred to a cryo-tube and put on ice for 2 to 5 minutes. Thereafter, 70 
µL of DMSO were added, mixed by pipetting and frozen at -80°C directly. 
6.2.4 Preparation of chemically competent E.coli cells 
A frozen cryo-culture of competent E.coli cells was streaked out on a LB medium plate using 
a sterile toothpick. Selective medium plates were used for cells carrying the appropriate 
antibiotic resistance gene. Incubation was performed at 37°C O/N. The following day a single 
colony was picked and used for inoculation of 5 mL of LB medium and incubated at 37°C 
O/N on a shaker. 
All solutions were put in the refrigerator and chilled down to 4 – 8°C. Tips and centrifugation 
tubes were stored at -20°C. 
The next day, 200 mL of 2x LB medium in a 2 L Erlenmeyer flask were inoculated with 5 mL 
of the O/N cultures under sterile conditions and incubated at 37°C until the solution reached 
an OD600 of 1.0. All further steps were carried out on ice to keep cells close to 4°C. Cells were 
transferred into a chilled centrifugation tube and centrifuged at 4°C and 1975x g in a GSA 
rotor for 15 minutes. For all centrifugation steps a SORVALL RC SC PLUS centrifuge. 
(Thermo Scientific Inc., Rockford, USA) was used. The supernatant was carefully discarded 
and 50 mL of icecold 10 mM NaCl were used for resuspending the pellet. The solution was 
chilled on ice for 10 minutes and then centrifuged again at 4°C and 1975x g. The supernatant 
was decanted and the pellet was resuspended in 50 mL of icecold 75 mM CaCl2 and incubated 
on ice for 35 minutes. After a last centrifugation step for 15 minutes at 4°C and 1975x g, the 
supernatant was again discarded and the pellet was resuspended in 3.0 mL of icecold 75 mM 
CaCl2. Thereafter, the solution was transferred to a sterile flask with 0.488 mL of autoclaved 
100% glycerole. The sample was mixed thoroughly, incubated on ice for 1 hour and then 
aliquots of 100 or 200 µL were transferred into 1.5 mL Eppendorf tubes kept on ice and 
shock-frozen in liquid nitrogen. Frozen aliquots were stored at -80°C until use. 
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6.2.5 Transformation of chemically competent E.coli cells 
One aliquot (100 µL) of chemically competent E.coli cells was thawed on ice. The respective 
ligation samples (up to 10 µL) were added and cells were kept on ice for 30 minutes. Heat 
shock was performed at 42°C for 45 seconds. Thereafter, the cells were incubated on ice for 2 
minutes. Subsequently 1.0 mL of SOC medium was added. To increase transformation 
efficiency, cells were incubated at room temperature for 15 minutes prior to incubation at 
37°C for 60 minutes on a shaking incubator (300 rpm). 
The cells were centrifuged at 4000 rpm for 2 minutes in an Eppendorf 5417C tabletop 
centrifuge and the pellet was resuspended in 100 to 200 µL of the supernatant, and plated on 
LB media plates containing the appropriate antibiotic if the cells carried a resistance gene. 
Plates were incubated at 37°C O/N. 
6.2.6 DNA digestion 
DNA samples were digested at 37°C for 1-2 h using the respective restriction enzymes and 
the corresponding buffers in a volume of 20-50 µL with approximately 2 µg of DNA (see 
below). Digested samples were separated by DNA gel electrophoresis or were used for further 
processing. 
Reagent Amount Company 
Restriction enzyme 0.5 – 2 µL Fermentas GmbH 
10x Tango buffer 4 - 10 µL Fermentas GmbH 
DNA sample (2 µg) X µL  
Nuclease free water Y µL to 
make up to 
the final 
volume of 
20 – 50 µL 
Fermentas GmbH 
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6.2.7 Dephosphorylation of digested vectors 
Digested vector samples were dephosphorylated with 5 U of Calf Intestine Alkaline 
Phosphatase (CIAP; 1 U/µL, Fermentas) by incubation at 37°C for 30 minutes followed by 
incubation at 85°C for 15 minutes to inactivate the enzyme. 
6.2.8 DNA ligation 
Ligation of digested DNA fragments was performed using T4 DNA ligase and the 
corresponding T4 DNA ligase buffer at a vector : insert ratio of 1 : 5. The concentration of 
DNA was determined by spectrophotometry. 
Ligation settings were pipetted in volumes from 10 to 25 µL with 2.5 units of T4 DNA ligase 
(see below). Incubation periods varied from 2 to 3 hours at room temperature. 
Reagent Amount Company 
T4 DNA ligase (5 U/µL) 0.5 µL Fermentas GmbH 
10x T4 DNA ligase buffer 1 – 2.5 µL Fermentas GmbH 
DNA insert   
Restricted vector   
Nuclease free water To make 
up the final 
volume 
Fermentas GmbH 
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6.2.9 Identification of positive clones by PCR 
PCR screening was used for fast identification of positive clones carrying the insert of 
interest. Single colonies grown on selective media after ligation were picked with sterile 
toothpicks and transferred to a PCR reaction mix (see table). 
In parallel, subcultures of each positive clone were prepared on LB medium plates containing 
selective antibiotics if E.coli cells carried the resistance gene. Plates were incubated O/N at 
37°C. 
 
Reagent Amount Company 
Dynazyme™ 2 DNA polymerase (2 
U/µL) 
0.5 µL Finnzymes Oy, Espoo, Finland 
10x buffer for Dynazyme™ DNA 
polymerase 
2 µL Finnzymes Oy 
dNTPs (10 mM each) 0.5 µL Applied Biosystems Inc., Foster City, USA 
Forward primer (10 pmol/µL) 0.5 µL Sigma-Aldrich Handels GmbH, Vienna, 
Austria 
Reverse primer (10 pmol/µL) 0.5 µL Sigma-Aldrich Handels GmbH 
Nuclease free water 16 µL Fermentas GmbH 
 
PCR programme: 
95°C → 6 minutes 
35 cycles: 
95°C → 30 seconds 
64°C → 40 seconds 
72°C → 1 minute 
Final elongation step: 
72°C → 8 minutes 
4°C → ∞ 
 
PCR products were analysed by DNA gel electrophoresis. 
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6.2.10 Amplification of DNA samples by PCR 
To amplify DNA samples, 0.1 to 1.0 µg of DNA template was added to the PCR reaction mix 
in a final volume of 50 µL (see below). Self-designed primers were purchased from Sigma 
Aldrich (Sigma-Aldrich Handels GmbH).  
 
Reagent Amount Company 
Phusion DNA polymerase (2 U/µL) 0.5 µL Finnzymes Oy 
5x HF buffer for Phusion DNA polymerase 10 µL Finnzymes Oy 
dNTPs (10 mM each) 1 µL Applied Biosystems Inc. 
Forward primer (10 pmol/µL) 1.5 µL Sigma-Aldrich Handels GmbH 
Reverse primer (10 pmol/µL) 1.5 µL Sigma-Aldrich Handels GmbH 
 
PCR programme: 
95°C → 5 minutes 
35 cycles: 
95°C → 30 seconds 
64°C → 40 seconds 
72°C → 1 minute 
final elongation step: 
72°C → 8 minutes 
4°C → ∞ 
 
PCR products were analysed by DNA gel electrophoresis. 
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6.2.11 DNA gel electrophoresis 
DNA samples were separated using Agarose gels containing EtBr. For a 1% (w/v) gel, 0.8 g 
of agarose were boiled in 80 mL of 1x TBE in a microwave oven until the solution was 
completely clear. For a 0.6% (w/v) gel, 0.48 g of agarose were boiled in 80 mL of 1x TBE.  
After cooling to approximately 60°C, 2 drops of a 0.07% EtBr solution (0.7 mg/mL; 
AppliChem GmbH, Darmstadt, Germany) were added. Gels were poured in the BioRad (Bio-
Rad Laboratories Ges.m.b.H., Vienna, Austria) tray and polymerized at RT in a fume hood to 
avoid inhalation of EtBr. 
Before loading, each DNA sample was mixed with the appropriate volume of Fermentas 6x 
DNA loading dye #R0611 (Fermentas GmbH). Gene RulerTM 100 bp DNA ladder marker 
(Fermentas GmbH) was used as a size marker. 
Gels were run at 70 to 80 V in the BioRad Sub-Cell GT Agarose Gel Electrophoresis System 
(Bio-Rad Laboratories Ges.m.b.H.) using 1x TBE as a running buffer. 
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6.2.12 DNA extraction from agarose gels using the QIAquick Gel 
Extraction Kit 
Extraction of DNA from agarose gels was done using the QIAquick Gel Extraction Kit 
(QIAGEN) according to the manufacturer’s protocol. All centrifugation steps were performed 
in an Eppendorf 5417C tabletop centrifuge (Eppendorf AG). 
 
Procedure: 
1.) Excise the DNA fragment from the agarose gel with a clean, sharp scalpel 
2.) Weigh the gel slice in a colorless tube. Add 3 volumes of Buffer QG to 1 volume of 
gel (100 mg correspond to 100 µL) 
3.) Incubate at 50°C for 10 min. To completely dissolve the gel, vortex the tube every 2-3 
min during the incubation. 
4.) After the gel slice has completely dissolved, the color of the mixture must be yellow 
(similar to Buffer QG without dissolved agarose). 
5.) Add 1 gel volume of isopropanol to the sample and mix. 
6.) Place a QIAquick spin column in a provided 2 mL collection tube. 
7.) To bind DNA, apply the sample to the QIAquick column, and centrifuge for 1 min. 
8.) Discard flow-through and place QIAquick column back in the same collection tube. 
9.) Recommended: Add 0.5mL of Buffer QG to QIAquick column and centrifuge for 1 
min 
10.) To wash, add 0.75 mL of Buffer PE to QIAquick column and centrifuge for 1 min. 
11.) Discard the flow-through and centrifuge the QIAquick column for an additional 1 min 
at 13000 rpm. 
12.) Place QIAquick column into a clean 1.5 mL microcentrifuge tube. 
13.) To elute DNA, add 50 µL of Buffer EB (10 mM Tris-CL, pH 8.5) or water to the 
center of the QIAquick membrane and centrifuge the column for 1 min. Alternatively, for 
increased DNA concentration, add 30 µL elution buffer to the center of the QIAquick 
membrane, let the column stand for 1 min, and then centrifuge for 1 min. 
The eluted DNA was applied to the column a second time and centrifuged as before to 
increase the purity of the DNA sample. 
DNA concentration was measured by spectrophotometry at 260 nm and 280 nm. DNA was 
stored at -20°C if not processed directly. 
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6.2.13 DNA sequencing 
DNA samples were sequenced at MWG Eurofins Operon (Eurofins MWG Operon, 
Ebersberg, Germany). DNA samples (50 – 100 ng/µL) in volumes of 15 – 20 µL were sent in 
for sequencing. 
Standard T7 polymerase primers were used. If internal primers were needed, they were 
purchased from Sigma Aldrich (Sigma-Aldrich Handels GmbH) and diluted to a working 
concentration of 2 pmol/µL in a volume of 15 µL according to the guidelines for internal 
primers from MWG (Eurofins MWG Operon). 
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6.3 Protein purification 
6.3.1 Preparation of SDS-PAGE gels 
Gels were prepared using the Biometra Minigel gel electrophoresis system (Biometra 
biomedizinische Analytik GmbH, Goettingen, Germany) 
Separating gel* Reagent 
15% 17% 
Stacking gel 
Polyacrylamid 
solution 
10 mL 11.3 mL 0.7 mL 
Lower buffer 5 mL 5 mL 1.1 mL 
ddH2O 5 mL 3.6 mL 2.6 mL 
TEMED 10 µL 10 µL 5 µL 
10% APS 60 µL 60 µL 30 µL 
* amounts to prepare 3 minigels 
6.3.2 Protein gel electrophoresis 
12 µL of the protein solution were mixed with 4 µL of 4x protein sample buffer, boiled at 
95°C for 15 minutes and loaded on the gel. Fermentas Page Ruler™ 8-16% Tris-glycerine 
SDS-PAGE marker was used as a molecular weight marker. The stacking gel was run at 20 
mA. When the marker front reached the separating gel 30 mA were used. 
6.3.3 Coomassie staining and destaining of SDS-PAGE gels 
Gels were stained with Coomassie staining solution (Coomassie brilliant blue G250) on a 
shaker at room temperature for 1 hour or O/N incubation. The staining solution was discarded 
and gels were destained at room temperature. 
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6.3.4 Silver staining of SDS-PAGE gels 
A silver staining kit (Bio-Rad Laboratories Ges.m.b.H., Vienna, Austria) was used for the 
detection of proteins separated by SDS-PAGE. The staining procedure was carried out 
according to the following protocol: 
 
1) Incubate the gel for 30 minutes in solution 1 (50% methanol, 12% acetic acid in 
ddH2O) on a shaker.  
 
2) Change to solution 2 (10% ethanol, 5% acetic acid in ddH2O) and incubate the gel for 
30 minutes changing to fresh solution 2 every 10 minutes. 
 
3) Wash the gel for 5 minutes in BIORAD OXIDIZER (cat. 161-0444) covered with 
aluminium foil. 
BIORAD OXIDIZER stock solution is 10x concentrated and has to be diluted 1:10 in 
ddH2O. 
 
4) Wash for 4 times (5 minutes each) in ddH2O. 
 
5) Incubate the gel in BIORAD Silver Nitrate (cat. 161-0445) for 5 minutes covered with 
foil on a fluorescent box and thereafter, for 25 minutes on a shaker. 
The stock solution is 10 x concentrated and has to be diluted 1:10 in ddH2O. 
 
6) Discard silver nitrate solution and add BIORAD DEVELOPER (cat. 161-0447; 3.2 g 
in 100 mL ddH2O) whilst shaking to avoid precipitates sticking to the gel. 
Do 2 quick changes (2 minutes each) and then a third change until the gel reaches 
optimum staining. 
 
7) Stop the developing reaction by incubation in 1% (v/v) acetic acid for about 2 minutes. 
 
8) The gel can be stored in ddH2O. 
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6.3.5 Immunoblotting 
Separated proteins were transferred onto a Whatman® Protran® Nitrocellulose Transfer 
membrane with 0.2 µm pore size (Whatman GmbH, Dassel, Germany) using an Amersham 
Biosciences TE22 Tank Transfer Unit (GE Europe GmbH, Munich, Germany) for 1 hour in a 
blotting chamber at 150 mA. 
Scheme: 
Negative pole 
↓ 
Cassette for blotting chamber 
↓ 
Sponge 
↓ 
Wet towel 
↓ 
Whatman Paper 
↓ 
Gel 
↓ 
Nitrocellulose membrane 
↓ 
Whatman paper 
↓ 
Wet towel 
↓ 
Sponge 
↓ 
Cassette for blotting chamber 
↓ 
Positive pole 
 
(all equilibrated in transfer buffer) 
 
Thereafter, the membrane was saturated O/N with blocking buffer (2.5 g of milk powder in 50 
mL of TBS containing 0.1% (v/v) of Tween 20) at 4°C. The next day, the membrane was 
washed with 15 mL of TBS/0.1% (v/v) Tween 20 for 10 minutes on a shaker at room 
temperature, a step that was repeated twice. Then the membrane was incubated with the 
primary antibody specific for the His-tag of the protein, a mouse Penta-His™ IgG1 antibody 
(QIAGEN) diluted 1:4000 in TBS/0.1% (v/v) Tween 20 supplemented with BSA (4% (w/v). 
After an incubation period of 2 hours, the antibody solution was discarded and the membrane 
was washed 3 times as described above. 
Thereafter, the secondary antibody, an anti-mouse IgG1 (H&L) HRP-linked antibody (Cell 
Signaling Technology Inc, Danvers, USA) was added at a dilution range of 1:4000 to 1:10000 
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in blocking buffer (or TBS/0.1% (v/v) Tween 20/4% BSA, alternatively). The membrane was 
incubated with the secondary antibody for 1 to 2 hours followed by 3 washing steps as 
described above. 
Finally, the membrane was soaked in the Lumigen™ PS-3 detection reagent (GE Healthcare 
UK Ltd, Birminghamshire, UK) which was prepared according to the manufacturer’s protocol 
and was used for incubated for 5 minutes. The solution was drained off the membrane and the 
membrane was covered with a sheet protector and fixed in a Hyperfilm detection box. An 
Amersham Hyperfilm™ MP (GE Europe GmbH, Munich, Germany) was exposed to the 
membrane in the darkroom. Exposure times had to be determined empirically. Films were 
developed in an AGFA CP1000 developing unit (Agfa Graphics Germany GmbH & Co. KG, 
Düsseldorf, Germany) 
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6.3.6 Protein test expression 
A frozen stock of E.coli BL21(DE3)pLysS cells (Invitrogen GmbH, Lofer, Austria) 
 carrying the desired vector was used for inoculation of 5 mL of LB medium supplied with the 
necessary selective antibiotic. Cells were grown at 37°C in an incubator rotating at 180 rpm 
for 14 to 16 hours. 1.7 mL of this pre-culture were then used to inoculate 50 mL of fresh LB 
medium containing the selection antibiotic. This culture was then grown to an OD600 of 0.6 to 
1.0. 
Before protein expression was induced, a 1 mL sample of the suspension was taken and 
centrifuged at 13000 rpm for 2 minutes in an Eppendorf 5417C tabletop centrifuge 
(Eppendorf AG). The supernatant was discarded and the pellet was resuspended in 100 µL of 
1x protein sample buffer and stored on ice. 
Protein expression was induced by the addition of IPTG (final concentration of 0.4 mM). 
Thereafter, a sample (500 µL) of the cell suspension was collected and centrifuged for 2 
minutes at 17900x g every hour. The supernatant was discarded and the pellet was 
resuspended in 50 µL of 1x protein sample buffer and stored on ice. 
After 6 hours of incubation at 37°C and 200 rpm the remaining cells were harvested by 
centrifugation at 4000x g and 4°C for 30 minutes in a SORVALL RC SC PLUS centrifuge 
(Thermo Scientific Inc.). The supernatant was carefully decanted and the pellet was 
resuspended in Lysis buffer (50 mM Tris/HCl pH = 7.5, 0.5 M NaCl, 30 mM imidazole). To 
lyse the cells the sample was frozen in liquid nitrogen and thawed at 37°C, which was 
repeated twice. If the cell lysate was very viscous, 5 µg/mL of DNase were added and 
incubated shaking gently for 30 to 60 minutes at RT. 
Thereafter, the cell suspension was centrifuged at 15000x g and 4°C for 20 minutes in a 
SORVALL RC SC PLUS centrifuge (Thermo Scientific Inc.). The supernatant containing the 
solubly expressed proteins was stored at 4°C. The pellet was resuspended in 5 mL of 6M urea 
and centrifuged under the same conditions as before. The supernatant containing the insolubly 
expressed protein fraction was stored at 4°C. 
To monitor protein expression over time, 12 µL of the soluble and insoluble fractions as well 
as of each sample taken every hour were loaded on SDS-PAGE gels (15 or 17%, page 29). 
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6.3.7 Protein expression under salt stress 
15 mL of TB medium containing the respective selective antibiotic were inoculated with 
E.coli BL21(DE3)pLysS (Invitrogen GmbH) cells containing a vector with the gene of 
interest using a sterile toothpick. Cells were grown O/N at 30°C shaking at 200 rpm. 
The next day the culture was diluted 1:30 in fresh TB medium supplemented with the 
selection antibiotic and cells were grown to an OD600 of 2.0 at 30°C and 200 rpm. Thereafter, 
salt stress was induced by the addition of 10 mM betaine, 0.5 M sorbitol and 4% NaCl and 
cells were incubated at 16°C and 180 rpm for 60 minutes. 
One aliquot (1 mL) was collected and centrifuged at 1700x g for 2 minutes in a tabletop 
centrifuge. The supernatant was discarded and the pellet was resuspended in 100 µL of 1x 
protein sample buffer. Protein expression was induced by the addition of IPTG (final 
concentration of 0.4 mM) and cells were cultured at 16°C rotating at 180 rpm. Samples (500 
µL) were taken at different timepoints to monitor protein expression. All samples were 
centrifuged at 1700x g for 2 minutes in a tabletop centrifuge. Supernatants were discarded and 
pellets were resuspended in 50 µL of 1x protein sample buffer. 
Protein expression was induced for 16 hours. Cells were harvested by centrifuging at 5000x g 
and 4°C for 30 minutes in a SORVALL RC SC PLUS centrifuge (Thermo Scientific Inc.). 
Supernatants were discarded and the pellet was resuspended in lysis buffer (50 mM Tris/HCl 
pH = 7.5, 0.5 M NaCl, 30 mM imidazole; one tenth of the original culture volume). Cells 
were lysed by freezing in liquid nitrogen and thawing in a 37°C waterbath. These steps were 
repeated twice. Thereafter, 5 µg/mL of DNase were added and incubated at room temperature 
shaking gently for 30 to 60 minutes. 
Thereafter, the cell suspension was centrifuged at 20000x g and 4°C for 30 minutes in a 
SORVALL RC SC PLUS centrifuge (Thermo Scientific Inc.) and the supernatant containing 
the solubly expressed proteins was stored at 4°C. The pellet was resuspended in 6 M urea 
(one tenth of the original culture volume). This suspension was centrifuged under the same 
conditions as before. The supernatant containing the insolubly expressed protein fraction was 
stored at 4°C. 
To monitor protein expression over time, 12 µL of the soluble and the insoluble fraction as 
well as of each sample taken at the different time-points were loaded on SDS-PAGE gels (15 
or 17%, page 29). 
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6.3.8 Protein Expression at 16°C 
A frozen stock of E.coli BL21(DE3)pLysS (Invitrogen GmbH) carrying the desired vector 
was used for inoculation of 5 mL of LB medium supplemented with the respective selective 
antibiotic. Cells were grown at 37°C in a shaking incubator at 180 rpm for 14 to 16 hours. 1.7 
mL of this culture were used for inoculation of 50 mL of fresh LB medium containing the 
selective antibiotic and this culture was then grown at 30°C to an OD600 of 0.6 to 1.0. 
Before induction of protein expression, a 1 mL aliquot of the suspension was collected and 
centrifuged at 17900x g for 2 minutes in a tabletop centrifuge. The supernatant was discarded 
and the pellet was resuspended in 100 µL of 1x protein sample buffer and stored on ice. 
Protein expression was induced by the addition of IPTG (final concentration of 0.4 mM) and 
the incubation temperature was reduced to 16°C. Thereafter, several samples (500 µL) were 
taken at indicated timepoints (Fig. 18) and centrifuged for 2 minutes at 17900x g a tabletop 
centrifuge. Supernatants were discarded and pellets were resuspended in 50 µL of 1x protein 
sample buffer. Samples were stored on ice and boiled at 95°C for 15 minutes prior to loading 
on an SDS-PAGE gel. 
After 20 hours of incubation at 16°C and 200 rpm, cells were harvested by centrifugation at 
4000x g and 4°C for 30 minutes in a SORVALL RC SC PLUS centrifuge (Thermo Scientific 
Inc.). The supernatant was decanted carefully and the pellet was resuspended in lysis buffer 
(50 mM Tris/HCl pH = 7.5, 0.5 M NaCl, 30 mM imidazole). Cells were lysed by three cycles 
of alternating freezing in liquid nitrogen and thawing at 37°C. If the cell lysate was very 
viscous, 5 µg/mL of DNase were added and incubated at room temperature shaking gently for 
30 to 60 minutes. 
Thereafter, the cell suspension was centrifuged at 15000x g and 4°C for 20 minutes in a 
SORVALL RC SC PLUS centrifuge (Thermo Scientific Inc.) and the supernatant containing 
the solubly expressed proteins was stored at 4°C. The pellet was resuspended in 6 M urea and 
centrifuged at the same conditions as before. The supernatant containing the insolubly 
expressed protein fraction was stored at 4°C. 
To monitor protein expression over time, 12 µL of the soluble and the insoluble fraction as 
well as of each sample taken at the different time-points were loaded on SDS-PAGE gels (15 
or 17%, page 29). 
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6.3.9 Affinity purification of protein samples 
Purification of His-tagged proteins was performed using the ÄKTATM prime protein 
purification system (GE Europe GmbH, Munich, Germany) according to the manufacturer’s 
instructions. 
The His-Trap FF crude 1 mL column (GE Europe GmbH, Munich, Germany) was 
equilibrated with 5 to 10 column volumes of lysis buffer. 
The protein solution was sterile filtered through a MILLEX GV low protein filter unit (0.22 
µm; Millipore Corporation, Billerica, USA) and loaded onto the column at a flowrate of 1 
mL/min with a backpressure maximum of 0.3 MPa. To elute the protein, a linear gradient 
starting with 100% of lysis buffer (50 mM Tris/HCl pH = 7.5, 0.5 M NaCl, 30 mM imidazole) 
and continuously increasing amounts of elution buffer reaching a final concentration of 100% 
of elution buffer (50 mM Tris/HCl pH = 7.5, 0.5 M NaCl, 500 mM imidazole) was used. 
Eluted proteins were collected in fractions of 1.5 mL and analysed by SDS-PAGE (12 to 17% 
gels) prior to dialysis against PBS. 
The His-Trap FF crude column as well as the ÄKTATM system were washed and equilibrated 
with ddH2O followed by ethanol (20% (v/v)). 
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6.3.10 Dialysis of protein samples 
Dialysis membranes with a molecular weight cut off (MWCO) of 6 - 8 kDa (Spectra/Por®, 
Spectrum Europe B.V., Breda, The Netherlands) were used. Membranes were prepared for 2 
hours at 60°C in 2000 mL pre-warmed dialysis preparation buffer with sporadic stirring. This 
step had to be repeated once. Thereafter, the membranes were incubated for 2 hours at 60°C 
in pre-warmed ddH2O. The water was changed several times until the solution was 
completely clear. Thereafter, the solution was slowly chilled to 4°C. Dialysis membranes 
were stored in ddH2O containing chloroform (1 mL/L) at 4°C. 
6.3.11 BCA assay 
Protein concentrations were determined using the Pierce Endogen BCA (Thermo Scientific 
Inc., Rockford, USA) assay according to the manufacturer’s protocol (microplate procedure). 
Preparation of the BCA™ working reagent: 
Prepare working reagent by mixing 50 parts of BCA™ Reagent A with 1 part of BCA™ 
Reagent B. (e.g. 5 mL of Reagent A with 100 µL of Reagent B) 
 
Microplate procedure protocol: 
1. Pipette 25 µL of each standard or unknown sample replicate into a microplate well 
(working range = 20 – 2000 µg/mL). 
2. Add 200 µL of the working reagent to each well and mix the plate thoroughly on a 
plate shaker for 30 seconds. 
3. Cover Plate and incubate at 37°C for 30 minutes. 
4. Cool plate to RT. 
5. Measure the absorbance at 562 nm. 
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6.4 Buffers and solutions 
10x TBE solution: 
54 g Tris base 
27.5 g Boric acid 
20 mL 0.5 M EDTA solution / or: 4.65 g (Na4EDTA) 
Fill up to 500 mL with ddH2O. 
 
TB Amp medium: 
24 g yeast extract 
12 g peptone 
4 mL 100% glycerol 
Fill up to 900 mL with ddH2O and autoclave. 
Meanwhile: 
2.31 g KH2PO4 
12.54 g K2HPO4 
Fill up to 100 mL with ddH2O and do sterile filtration. 
When autoclaved solution has cooled down add the 100 mL of the other solution and finally 
add 1 mL of Ampicillin (stock: 100 mg/mL). Store at 4°C. 
 
LB Amp medium: 
5 g NaCl 
10 g peptone 
5 g yeast extract 
Fill up to 1000 mL with ddH2O 
Autoclave and when cooled down (handwarm) add 1 mL Amp (stock: 100 mg/mL) under 
laminar flow/sterile conditions and keep in fridge. 
 
 39 
LB medium: 
5 g NaCL 
10 g peptone 
5 g yeast extract 
Fill up to 1000 mL with ddH2O 
Autoclave and store at RT. 
 
LB Amp plates: 
5 g NaCL 
10 g peptone 
5 g yeast extract 
15 g Agar 
Fill up to 100 mL with ddH2O 
Autoclave and when cooled down (handwarm) add 1 mL Amp (stock: 100 mg/mL) and pour 
plates under laminar flow/sterile conditions. 
 
LB plates: 
5 g NaCL 
10 g peptone 
5 g yeast extract 
15 g Agar 
Fill up to 100 mL with ddH2O 
Autoclave and pour plates under laminar flow/sterile conditions. 
 
2 M NaCl: 
11.69 g NaCl 
Fill up to 100 mL with ddH2O. 
 
50 mL 10 mM NaCl: 
29.22 mg of 2 M NaCl 
Fill up to 50 mL with ddH2O 
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50 mL 75 mM CaCl2: 
0.55 g CaCl2 
Fill up to 50 mL with ddH2O. 
 
10x PBS: 
80 g NaCl 
2 g KCl 
14.4 g Na2HPO4 
2.4 g KH2PO4 
 
pH = 7.4 (HCl/NaOH) 
Fill up to 1000 mL with ddH2O. 
 
Coomassie Brilliant Blue:     Destaining solution: 
1 g Coomassie brilliant blue G-250    100 mL methyl alcohol 
500 mL methyl alcohol     100 mL acetic acid 
100 mL acetic acid      800 mL ddH2O 
400 mL dd H2O 
Dissolve Brilliant Blue in methyl alcohol first O/N 
and then add the other substances because otherwise 
the Brilliant Blue won’t dissolve properly. 
 
Lysis buffer (50 mM Tris/HCl pH = 7.5, 0.5 M NaCl, 30 mM imidazole): 
6.057 g Tris 
29.22 g NaCl 
2.04 g imidazole 
Fill up to 1000 mL with ddH2O pH = 7.5 with HCl 
 
Elution buffer (50 mM Tris/HCl pH = 7.5, 0.5 M NaCl, 500 mM imidazole): 
6.057 g Tris 
29.22 g NaCl 
34.04 g imidazole 
Fill up to 1000 mL with ddH2O pH = 7.5 with HCl 
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1 mg/mL DNase stock solution: 
Buffer: 10 mM Tris/Hcl pH = 7.5, 150 mM NaCl, 1 mM MgCl 
For 25 mL of buffer: 
0.03 g Tris 
0.219 g NaCl 
0.00508 g MgCl 
Dissolve 2 mg of DNase in 1 mL of buffer and when DNase has dissolved completely add 1 
mL of glycerol. 
 
Carbonate buffer (pH = 9.6): 
1.965 g Na2CO3 
2.645 g NaHCO3 
Ad 500mL of ddH2O 
 
Tissue culture media: 
HEK-TLR5 medium: 
500 mL DMEM (PAA Laboratories GmbH) 
10% FCS (PAA Laboratories GmbH) = 50 mL 
1 mL Gentamycin (10 g/118 mL) 
500 µL Blasticidin (10 mg/mL) 
 
CaCo-2 medium: 
500 mL DMEM (PAA Laboratories GmbH) 
10% FCS (PAA Laboratories GmbH) = 50 mL 
5 mL Glutamin (2.937 g/100 mL) 
1 mL Gentamycin (10 g/118 mL) 
 
UCФ medium 
500 mL Ultra Culture medium (Lonza Group Ltd., Basel, Switzerland) 
5 mL Glutamin (2.937 g/100 mL) 
2.5 mL β-mercaptoethanol (35 µL/50 mL) 
1 mL Gentamycin (10 g/118 mL) 
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N2 medium 
500 mL RPMI 1640 buffered with 25mM Hepes (Gibco®,Invitrogen GmbH) 
20% FCS (PAA Laboratories GmbH) 
10% DMSO 
1 mL Gentamycin (10 g/118 mL) 
 
(Note: Add FCS to RPMI1640 medium and then add DMSO dropwise whilst gently shaking!) 
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7 Results 
Toll-like receptor (TLR) ligands are discussed as possible adjuvants in allergy vaccines. We 
tested recombinant flagellin, a TLR5 ligand, on PBMC from allergic donors to analyse 
whether flagellin might be useful for developing new adjuvants for allergy vaccines. Different 
cell lines carrying TLR5 were used to establish a suited test protocol for the evaluation of 
TLR5 binding.  
 
7.1 Testing recombinant flagellin from S. typhimurium on 
peripheral blood mononuclear cells (PBMC) from birch pollen-
allergic patients 
PBMC of birch pollen-allergic patients were isolated and stimulated with recombinant 
flagellin in the presence or absence of autologous plasma. Cytokine secretion of different key 
cytokines was determined by ELISA. 
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Figure 2: IL-10 production of PBMC from a birch pollen-allergic patient in response to flagellin from S. 
typhimurium: PBMC (0.5x106 /96 flat-bottomed well) were incubated with either medium alone, different 
concentrations of lipopolysaccharide (LPS) or different concentrations of flagellin from Salmonella typhimurium 
for 48 hours in medium containing 20 µg/mL polymyxin B either in the presence (hatched bars) or absence 
(filled bars) of 20% autologous plasma. IL-10 secretion was determined by ELISA.  
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Patient 2 IL-10 ELISA
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Figure 3: IL-10 production of PBMC from a birch pollen-allergic patient in response to flagellin from S. 
typhimurium: PBMC (0.5x106 /96 flat-bottomed well) were incubated with either medium alone, different 
concentrations of lipopolysaccharide (LPS) or different concentrations of flagellin from Salmonella typhimurium 
for 48 hours in medium containing 20 µg/mL polymyxin B either in the presence (hatched bars) or absence 
(filled bars) of 20% autologous plasma. IL-10 secretion was determined by ELISA. 
 
Figures 2 and 3 show that stimulation of PBMC with flagellin led to increased IL-10 
production compared to the medium controls. Different concentrations of flagellin were tested 
and the concentration of 50 ng/mL triggered the highest IL-10 secretion. Presumably, higher 
amounts of flagellin were cytotoxic and killed the cells. IL-10 synthesis was increased in the 
presence of 20% autologous plasma (hatched bars) as compared to stimulation without 
autologous plasma (filled bars). Stimulation with LPS induced IL-10 secretion in the presence 
of autologous plasma. 
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Figure 4: IFN-γ production of PBMC from a birch pollen-allergic patient in response to flagellin from S. 
typhimurium: PBMC (0.5x106 /96 flat-bottomed well) were incubated with medium alone, different 
concentrations of lipopolysaccharide (LPS) or different concentrations of flagellin from Salmonella typhimurium 
for 48 hours in medium containing 20 µg/mL polymyxin B either in the presence (hatched bars) or absence 
(filled bars) of 20% autologous plasma. IFN-γ secretion was determined by ELISA. 
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Figure 5: IFN-γ production of PBMC from a birch pollen-allergic patient in response to flagellin from S. 
typhimurium: PBMC (0.5x106 /96 flat-bottomed well) were incubated with medium alone, different 
concentrations of lipopolysaccharide (LPS) or different concentrations of flagellin from Salmonella typhimurium 
for 48 hours in medium containing 20 µg/mL polymyxin B either in the presence (hatched bars) or absence 
(filled bars) of 20% autologous plasma. IFN-γ secretion was determined by ELISA. 
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Figures 4 and 5 show that stimulation with flagellin led to increased IFN-γ production as 
compared to medium alone. This effect was enhanced by the presence of autologous plasma.  
 
We also assessed the production of TNF-α in response to flagellin. No production of TNF-α 
was detected. 
 
In summary, we found a weak induction of the TH1-type cytokine IFN-γ and a stronger 
induction of the immunosuppressive cytokine IL-10. We considered flagellin as a potential 
adjuvant for allergy vaccination.  
 
7.2 Establishing a test system for TLR5 triggering 
7.2.1 Human embryonic kidney (HEK) 293 cells stably transfected with 
TLR5  
We stimulated HEK-293 cells stably transfected with TLR5 (HEK-293/TLR5) with different 
concentrations of flagellin (Invitrogen GmbH) and determined IL-8 secretion by ELISA. 
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Figure 6: IL-8 production of HEK-293/TLR5 cells in response to flagellin from S. typhimurium: HEK-
293/TLR5 cells were seeded in a flatbottomed 96 well plate (40000 cells/well) and incubated for 24 hours. 
Medium was removed and replaced by medium containing the specific stimuli. After 20 hours IL-8 production 
was determined by ELISA. 
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Figure 6 shows that stimulation of HEK-293/TLR5 cells with flagellin induced the production 
of IL-8 (black bars) whereas lipopolysaccharide (LPS), a TLR4 ligand, which served as a 
negative control did not induce IL-8 synthesis. The synthesis of IL-8 after stimulation with 
flagellin was dose dependent. 
 
7.2.2 CaCo-2 cells 
This immortalized cell-line derived from human epithelial colorectal adenocarcinoma cells 
shows the ability to differentiate into small intestinal-like cells after confluent growth and it 
carries TLR5. We were interested in the effects of flagellin stimulation on these cells as they 
can be used as a model system for intestinal functions.  
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Figure 7: IL-8 production of CaCo-2 cells in response to flagellin from S. typhimurium: CaCo-2 cells were 
seeded in a flatbottomed 96 well plate (40000 cells/well) and incubated for 24 hours. Medium was removed and 
replaced by medium containing the specific stimuli. After 20 hours IL-8 production was determined by ELISA. 
 
Figure 7 shows that stimulation with flagellin triggered CaCo-2 cells to synthesize IL-8 in a 
dose dependent manner. LPS was not able to induce IL-8 secretion. HEK-293/TLR5 produced 
higher levels of IL-8 (Fig.6) as compared to CaCo-2 cells (Fig.7). 
 
Moreover, the HEK-293/TLR5 cell line was more convenient to work with in the tissue 
culture as cells were easier to detach and showed enhanced growth compared to the CaCo-2 
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cells. Therefore, we decided to use the HEK-293/TLR5 cell line as our standard cell line to 
evaluate TLR5 binding. 
 
7.3 Evaluating the influence of heat-labile serological factors on 
TLR5 triggering 
As serological factors might play a role in the signalling cascade of TLR, we examined 
whether heat-labile serological factors had an influence on the biological capacity of 
recombinant flagellin to trigger TLR5. 
0
2000
4000
6000
8000
10000
12000
14000
16000
Medium
+ FCS
inact.
Med +
FCS NOT
inact.
LPS 10
ng/mL +
FCS
inact.
LPS 10
ng/mL +
FCS NOT
inact.
Flag 50
ng/mL +
FCS
inact.
Flag 50
ng/mL +
FCS NOT
inact.
Flag 10
ng/mL +
FCS
inact.
Flag 10
ng/mL +
FCS NOT
inact.
Flag 2
ng/mL +
FCS
inact.
Flag 2
ng/mL +
FCS NOT
inact.
IL
-8
 [
p
g
/m
L
]
 
Figure 8: Influence of serological factors on TLR5 stimulation by flagellin: HEK-293/TLR5 cells were 
seeded in a flatbottomed 96 well plate (40000 cells/well) and incubated for 24 hours. Medium was removed and 
replaced by medium containing the specific stimuli. Medium either supplemented with inactivated FCS (full 
bars) or non-inactivated FCS (hatched bars) was used. After 20 hours IL-8 secretion in the cell supernatants was 
determined by ELISA. 
 
Figure 8 shows the IL-8 production of HEK-TLR5 cells in response to different 
concentrations of recombinant flagellin from S. typhimurium (Invitrogen GmbH) either in the 
presence of 10% FCS inactivated by incubation at 56°C for 30 minutes (full bars) or non-
inactivated FCS (hatched bars). No difference in the ability of flagellin to trigger TLR5 was 
observed. The medium control and the negative control did not show different results when 
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non-inactivated FCS was added. We decided to use heat-inactivated FCS in our standard 
protocols. 
 
To further investigate the possible adjuvant activities of flagellin from S. typhimurium we 
wanted to recombinantly express the protein in bacteria to have sufficient amounts of the 
protein and save costs. 
 
7.4 Amplification and cloning of DNA encoding flagellin from S. 
typhimurium into pETBlue-2 vector 
Prior to isolation of the genomic DNA of Salmonella typhimurium using the QIAGEN 
DNeasy blood and tissue kit, Salmonella typhimurium (ATCC® 35987) was cultured in LB 
medium. DNA samples were separated on a 0.6% (w/v) agarose gel containing EtBr. 
 
Figure 9: Genomic DNA of S. typhimurium: Two DNA samples (Lanes 1&2) were separated on a 0.6% (w/v) 
agarose gel containing EtBr Lane M: Fermentas DNA High range marker ready to use 
 
Figure 9 shows very intense bands in a size of more than 10 kb resulting from the genomic 
DNA of S. typhimurium in lanes 1 and 2. Weak bands were detected in both lanes resulting 
from RNA and degraded DNA fragments. 
 
Both samples of genomic DNA were then used as templates for PCR with primers specific for 
the flagellin protein (Fig. 10). 
 
Forward primer: GAGACCATGGCTCTGGGCACCGCTATCGA 
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Reverse primer: GAGACTCGAGACGCAGTAAAGAGAGGACG 
 
Bases matching the DNA sequence of flagellin are underlined. Bases encoding restriction 
sites for NcoI and XhoI are shown in bold. Primers were designed excluding the signal 
peptide of flagellin since it is not necessary for the antigenic capacity of the protein. 
 
        1 aaggaaaaga tcatggcaca agtcattaat acaaacagcc tgtcgctgtt gacccagaat 
       61 aacctgaaca aatcccagtc cgctctgggc accgctatcg agcgtctgtc ttccggtctg 
      121 cgtatcaaca gcgcgaaaga cgatgcggca ggtcaggcga ttgctaaccg ttttaccgcg 
      181 aacatcaaag gtctgactca ggcttcccgt aacgctaacg acggtatctc cattgcgcag 
      241 accactgaag gcgcgctgaa cgaaatcaac aacaacctgc agcgtgtgcg tgaactggcg 
      301 gttcagtctg ctaacagcac caactcccag tctgacctcg actccatcca ggctgaaatc 
      361 acccagcgtc tgaacgaaat cgaccgtgta aatggccaga ctcagttcag cggcgtgaaa 
      421 gtcctggcgc aggacaacac cctgaccatc caggttggtg ccaacgacgg tgaaactatc 
      481 gatatcgatc tgaagcagat caactctcag accctgggtc tggatacgct gaatgtgcaa 
      541 caaaaatata aggtcagcga tacggctgca actgttacag gatatgccga tactacgatt 
      601 gctttagaca atagtacttt taaagcctcg gctactggtc ttggtggtac tgacgagaaa 
      661 attgatggcg atttaaaatt tgatgatacg actggaaaat attacgccaa agttaccgtt 
      721 acggggggaa ctggtaaaga tggctattat gaagtttccg ttgataagac gaacggtgag 
      781 gtgactcttg ctgcggtcac tcccgctaca gtgactactg cgacagcact gagtggaaaa 
      841 atgtacagtg caaatcctga ttctgacata gctaaagccg cattgacagc agcaggtgtt 
      901 accggcacag catctgttgt taagatgtct tatactgata ataacggtaa aactattgat 
      961 ggtggtttag cagttaaggt aggcgatgat tactattctg caactcaaga taaagatggt 
     1021 tccataagta ttgatactac gaaatacact gcagataacg gtacatccaa aactgcacta 
     1081 aacaaactgg gtggcgcaga cggcaaaacc gaagtcgtta ctatcgacgg taaaacctac 
     1141 aatgccagca aagccgctgg tcatgatttc aaagcagaac cagagctggc ggaacaagcc 
     1201 gctaaaacca ccgaaaaccc gctgcagaaa attgatgctg ctttggcaca ggttgacacg 
     1261 ttacgttctg acctgggtgc ggtacagaac cgtttcaact ccgctattac caacctgggc 
     1321 aacaccgtaa acaacctgtc ttctgcccgt agccgtatcg aagattccga ctacgcgacc 
     1381 gaagtctcca acatgtctcg cgcgcagatt ctgcagcagg ccggtacctc cgttctggcg 
     1441 caggcgaacc aggttccgca aaacgtcctc tctttactgc gttaa 
Figure 10: DNA sequence encoding flagellin from S. typhimurium (1485 bp, NCBI Accession No.: 
M11332,[40]): Primer base pairing sequences are underlined 
  
Thereafter, PCR products were checked on a 1% (w/v) agarose gel containing EtBr and bands 
of the correct size indicating the expected DNA fragment were excised under UV light and 
used for DNA extraction by the QIAquick Gel Extraction Kit. One sample was used for 
further steps. The other sample was stored at -20°C. 
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Prior to ligation into the pETBlue-2 vector from Novagen (EMD Chemicals Inc., San Diego, 
USA), the excised DNA sample and the vector were digested with restriction enzymes NcoI 
and XhoI. The vector was dephosphorylated by CIAP treatment to prevent religation. After 
ligation of the excised DNA into the vector, the sample was used for transformation of E.coli 
TOP10 cells. Ligation was checked by PCR screening using the grown colonies as templates 
and the primers mentioned above. PCR products were checked by DNA gel electrophoresis. 
We used this vector as it allowed the addition of a histidine-tag to the C-terminus of the 
protein sequence. This His-tag facilitates the purification of the protein of interest. 
 
Figure 11: Flagellin in pETBlue-2 vector colony screening: 4 colonies (Lanes 1-4) were checked for 
successful ligation of the flagellin sequence into the pETBlue-2 vector in a 1% (w/v) agarose gel containing EtBr 
Lane M: Fermentas 100 bp DNA ladder marker 
 
Figure 11 shows that PCR of colonies 1 and 4 amplified bands with a size of 1500 bp that 
correlated with the calculated size of flagellin from S. typhimurium. Lanes 2 and 3 showed no 
bands at the expected size indicating that these clones did not carry the vector containing the 
correct insert. 
 
As only 2 positive clones were found, more colonies were picked and screened by PCR to 
identify additional clones containing the correct insert. PCR products were again checked by 
DNA gel electrophoresis and revealed more clones carrying the vector with the insert. 
 
To check whether those clones giving positive results in the PCR screening indeed carried the 
insert of interest, a plasmid preparation of an O/N culture of each individual colony was 
performed. The plasmid DNA was digested with the restriction enzymes NcoI and XhoI and 
loaded on a 1% (w/v) agarose gel containing EtBr. 
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Figure 12: Flagellin in pETBlue-2 vector NcoI/XhoI control digest: Plasmid DNA (Lanes 1 and 2) was 
digested with restriction enzymes NcoI and XhoI and checked on a 1% (w/v) agarose gel containing EtBr. Lane 
M: Fermentas 100 bp DNA ladder marker 
 
Figure 12 shows that 2 clones (Lanes 1 and 2) contained a DNA insert in the size of 1500 bp 
matching the expected size for flagellin from S. typhimurium. 
Isolated plasmid DNA samples of positive clones were sequenced by MWG (Eurofins MWG 
Operon, Ebersberg, Germany) using standard T7 primers. Obtained sequences were matched 
with the flagellin sequence (NCBI Accession No.: M11332, Fig.10) by BLAST analysis (data 
not shown). 
 
The DNA sequences of all clones contained several mutations in the sequence encoding the 
N-terminal part of the protein. Therefore, the whole process was started again from the PCR 
with the genomic DNA sample as template and all steps were performed as described above. 
 
Finally, 3 clones were used for inoculation of 5 mL of LB Amp to perform plasmid 
preparation and digestion of the DNA samples with NcoI and XhoI. Digested DNA was 
analysed on a 1% (w/v) agarose gel containing EtBr. 
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Figure 13: Flagellin in pETBlue-2 vector NcoI/XhoI control digest: Plasmid DNA (Lanes 1-3) was digested 
with restriction enzymes NcoI and XhoI and checked on a 1% (w/v) agarose gel containing EtBr.Lane M: 
Fermentas 100 bp DNA ladder marker 
 
Figure 13 shows 3 positive clones (Lanes 1 to 3) carrying an insert with the correct size of 
approximately 1500 bp. DNA samples of positive clones were sequenced by MWG and 
matched with the flagellin sequence (NCBI Accession No.: M11332, Fig.10) by BLAST 
analysis. The sequences obtained after sequencing using the standard T7 primers showed that 
there were no mutations in the N-terminal part of the protein (data not shown). As the 
standard primers were not sufficient to obtain full-length sequences, internal primers were 
designed. The forward primer was designed according to the partial sequence and the 
pETBlue-2 DOWN primer was used as a reverse primer. The internal primers were then used 
for further sequencing of the samples. 
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Partial sequence of flagellin obtained after sequencing with standard T7 primers: 
CCCCTCTAGACTTACAATTTCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGA 
TCGGTACGGGCCTCTTCGCTATTACGCCAGCTTGCGAACGGTGGGTGCGCTGCAAGGCGA 
TTAAGTTGGGTAACGCCAGGATTCTCCCAGTCACGACGTTGTAAAACGACGGCCAGCGAG 
AGATCTTGATTGGCTAGCAGAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGC 
TCTGGGCACCGCTATCGAGCGTCTGTCTTCCGGTCTGCGTATCAACAGCGCGAAAGACGA 
TGCGGCAGGTCAGGCGATTGCTAACCGTTTTACCGCGAACATCAAAGGTCTGACTCAGGC 
TTCCCGTAACGCTAACGACGGTATCTCCATTGCGCAGACCACTGAAGGCGCGCTGAACGA 
AATCAACAACAACCTGCAGCGTGTGCGTGAACTGGCGGTTCAGTCTGCTAACAGCACCAA 
CTCCCAGTCTGACCTCGACTCCATCCAGGCTGAAATCACCCAGCGCCTGAACGAAATCGA 
CCGTGTATCCGGCCAGACTCAGTTCAACGGCGTGAAAGTCCTGGCGCAGGACAACACCCT 
GACCATCCAGGTTGGTGCCAACGACGGTGAAACTATCGATATCGATCTGAAGCAGATCAA 
CTCTCAGACCCTGGGTCTGGATACGCTGAATGTGCAACAAAAATATAAGGTCAGCGATAC 
GGCTGCAACTGTTACAGGATATGCCGATACTACGATTGCTTTAGACAATAGTACTTTTAA 
AGCCTCGGCTACTGGTCTTGGTGGTACTGACCAGAAAATTGATGGCGATTTAAAATTTGA 
TGATACGACTGGAAAATATTACGCCAAAGTTACCGTTACGGGGGGAACTGGTAAAGATGG 
CTATTATGAAGTTTCCGTTGATAAGACGAACGGTGAGGTGACTCTTGCTGGCGGTGCGAC 
TTCCCCGCTTACAGGTGGACTACCTGCGACAGCAACTGAGGATGTGAAAATGTACAAGTT 
GCAAATGCTGATTTGACAGAGCT 
 
Flagellin internal forward primer: GGTACTGACCAGAAAATTGATGGCG 
 
The sequence used for design of the internal forward primer is underlined. 
 
pETBlue-2 DOWN primer (bp 505-525 in the Novagen pETBlue-2 vector): 
GTTAAATTGCTAACGCAGTC 
 
Flagellin protein sequence (S. typhimurium): 
ALGTAIERLSSGLRINSAKDDAAGQAIANRFTANIKGLTQASRNANDGISIAQTTEGALN 
EINNNLQRVRELAVQSANSTNSQSDLDSIQAEITQRLNEIDRVNGQTQFSGVKVLAQDNT 
LTIQVGANDGETIDIDLKQINSQTLGLDTLNVQQKYKVSDTAATVTGYADTTIALDNSTF 
KASATGLGGTDEKIDGDLKFDDTTGKYYAKVTVTGGTGKDGYYEVSVDKTNGEVTLAAVT 
PATVTTATALSGKMYSANPDSDIAKAALTAAGVTGTASVVKMSYTDNNGKTIDGGLAVKV 
GDDYYSATQDKDGSISIDTTKYTADNGTSKTALNKLGGADGKTEVVTIDGKTYNASKAAG 
HDFKAEPELAEQAAKTTENPLQKIDAALAQVDTLRSDLGAVQNRFNSAITNLGNTVNNLS 
SARSRIEDSDYATEVSNMSRAQILQQAGTSVLAQANQVPQNVLSLLR- 
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Sequencing resulted in the following translated sequences of each clone: 
Clone 1 translated sequence: 
MALGTAIERLSSGLRINSAKDDAAGQAIANRFTANIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELAV
QSANSTNSQSDLDSIQAEITQRLNEIDRVSGQTQFNGVKVLAQDNTLTIQVGANDGETIDIDLKQINSQTLGLDT
LNVQQKYKVSDTAATVTGYADTTIALDNSTFKASATGLGGTDQKIDGDLKFDDTTGKYYAKVTVTGGTGKDGYYE
VSVDKTNGEVTLAGGATSPLTGGLPATATEDVKNVQVANADLTEAKAALTAAGVTGTASVVKMSYTDNNGKTIDG
GLAVKVGDDYYSATQNKDGSISINTTKYTADDGTSKTALNKLGGADGKTEVVSIGGKTYAASKAEGHNFKAQPDL
AEAAATTTENPLQKIDAALAQVDTLRSDLGAVQNRFNSAITNLGNTVNNLTSARSRIEDSDYATEVSNMSRAQIL
QQAGTSVLAQANQVPQTSSLYCVSSTTTTTTNVN- 
 
Clone 2 translated sequence: 
MALGTAIERLSSGLRINSAKDDAAGQAIANRFTANIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELAV
QSANSTNSQSDLDSIQAEITQRLNEIDRVSGQTQFNGVKVLAQDNTLTIQVGANDGETIDIDLKQINSQTLGLDT
LNVQQKYKVSDTAATVTGYADTTIALDNSTFKASATGLGGTDQKIDGDLKFDDTTGKYYAKVTVTGGTGKDGYYE
VSVDKTNGEVTLAGGATSPLTGGLPATATEDVKNVQVANADLTEAKAALTAAGVTGTASVVKMSYTDNNGKTIDG
GLAVKVGDDYYSATQNKDGSISINTTKYTADDGTSKTALNKLGGADGKTEVVSIGGKTYAASKAEGHNFKAQPDL
AEAAATTTENPLQKIDAALAQVDTLRSDLGAVQNRFNSAITNLGNTVNNLTSARSRIEDSDYATEVSNMSRAQIL
QQAGTSVLAQANQVPQTSSLTASRAPPPPPLMLIKLGVVIIVIINTPDCVSNLTVINYRIKAIR- 
 
Clone 3 translated sequence: 
MALGTAIERLSSGLRINSAKDDAAGQAIANRFTANIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELAV
QSANSTNSQSDLDSIQAEITQRLNEIDRVSGQTQFNGVKVLAQDNTLTIQVGANDGETIDIDLKQINSQTLGLDT
LNVQQKYKVSDTAATVTGYADTTIALDNSTFKASATGLGGTDQKIDGDLKFDDTTGKYYAKVTVTGGTGKDGYYE
VSVDKTNGEVTLAGGATSPLTGGLPATATEDVKNVQVANADLTEAKAALTAAGVTGTASVVKMSYTDNNGKTIDG
GLAVKVGDDYYSATQNKDGSISINTTKYTADDGTSKTALNKLGGADGKTEVVSIGGKTYAASKAEGHNFKAQPDL
AEAAATTTENPLQKIDAALAQVDTLRSDLGAVQNRFNSAITNLGNTVNNLTSARSRIEDSDYATEVSNMSRAQIL
QQAGTSVLAQANQVPQNVLSLLRLEHHHHHH- 
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The amino acid sequence of each clone was compared with the amino acid sequence of 
flagellin from S. typhimurium (NCBI Accession No.: AAA27072;[40] excluding the signal 
peptide) using the NCBI protein BLAST tool (Fig. 14). 
 
Figure 14:Amino acid sequence comparison of the cloned flagellin (Sbjct) and the published protein(NCBI 
Accession No.: AAA27072;[40];Query) by protein BLAST: One representative example is shown. 
 
All 3 clones contained mutations mainly in the central region of the protein at amino acids 
236 to 267 (Fig.14). The N- and the C-terminal regions of the protein contained hardly any 
mutations. As the same mutations were detected in all 3 clones, we assumed that the model 
sequence of flagellin was taken from another isotype of S. typhimurium.  This assumption was 
further supported by the fact that the central region of flagellin is known to be highly diverse 
amongst different bacterial species whereas the N- and C-terminal regions are highly 
conserved. Therefore, we used clone 3 for further experiments and kept frozen bacterial 
stocks of the other clones. 
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7.5 Protein expression and purification of recombinant flagellin 
from S. typhimurium 
7.5.1 Test expression of flagellin from S. typhimurium 
The vector containing the correct insert was transformed into E.coli BL21(DE3)pLysS cells 
and protein test expression of flagellin from S. typhimurium over a time period of 6 hours was 
performed. Expression was induced with 0.4 mM IPTG and protein expression over the 
investigated time course was checked by SDS-PAGE and staining with Coomassie Brilliant 
Blue. 
 
Figure 15: Test expression of flagellin from S. typhimurium: Samples were collected at different timepoints 
(Lanes 0–6h) after induction with IPTG and also samples representing the solubly expressed (Lane Sol.) and the 
insolubly expressed (Lane Insol.) protein fractions were collected. All samples were separated by SDS-PAGE 
(15%) and the gel was stained with Coomassie Brilliant Blue to detect proteins. Lane M: Fermentas 8-16% Tris-
glycerine SDS-PAGE marker 
 
The calculated size of recombinant flagellin including the His-tag was 49.9 kDa. Figure 8 
shows that the protein expression increased over the timecourse of 6 hours (Lanes 1h to 6h) as 
compared to the uninduced stage (Lane 0). Several proteins of lower as well as of higher 
molecular weight were detected. Prominent bands appeared indicating proteins of a molecular 
weight of approximately 25 kDa and 37 kDa. These proteins represented putative degraded 
products of flagellin. A band in the range of 49 kDa was visible in all lanes except for the 
insoluble protein fraction (Lane Insol.). This band probably resulted from the recombinant 
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flagellin protein. The majority of the proteins seemed to be solubly expressed as there were 
more intense bands in this fraction (Lane Sol.) as compared to the insolubly expressed protein 
fraction (Lane Insol.). 
 
The expression of His-tagged proteins over the time period of 6 hours was analysed by 
immunoblotting. Samples separated by SDS-PAGE were transferred onto nitrocellulose. After 
saturation of non-specific binding sites the sheet was incubated with a mouse anti Penta-His™ 
antibody. Detection was achieved by a secondary antibody, that was HRP-linked and the 
Lumigen™ detection reagent. 
 
Figure 16: Immunoblot of the recombinant flagellin protein from S. typhimurium: The same samples (Lanes 
0-Insol.) as described for Fig.8 were separated by SDS-PAGE (15%), blotted onto a nitrocellulose membrane 
and finally, detected with the Lumigen™ detection reagent and developed on a hyperfilm. Lane M: Fermentas 8-
16% Tris-glycerine SDS-PAGE marker 
 
Figure 16 shows that His-tagged proteins of 37, 50 and 72 kDa, respectively, were expressed. 
Interestingly, optimum expression was found 4 hours (Lane 4h) after induction. Longer 
induction seemed to lead to degradation of the proteins (Lanes 5h and 6h). The expected 
protein had a calculated size of 49.9 kDa and we were able to detect a protein at the 
approximate size of 50 kDa after induction with IPTG (Lanes 1h to 6h). This protein was also 
present in the soluble protein fraction (Lane Sol.) but not in the insolubly expressed protein 
fraction (Lane Insol.). Bands appeared in all fractions excluding the insolubly expressed 
protein fraction at approximately 37 kDa probably resulting from degradations. Another 
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prominent band was detected at 72 kDa, which can not result from dimers or multimers of the 
protein as flagellin has a calculated size of 49.9 kDa. 
To reduce the expression of other proteins than flagellin or to reduce degradations of the 
protein, we tried expression under salt stress as well as expression at 16°C. 
7.5.2 Test expression of flagellin from S. typhimurium under salt stress 
Protein expression under salt stress is one approach to ensure that only essential proteins are 
expressed. As a halophilic environment (mimicked in vitro by salt stress) means harsh 
conditions for E.coli cells, these cells will only synthesize essential proteins or proteins that 
are under the control of strong promoters.  
We performed salt stress by addition of 10 mM betaine, 0.5 M sorbitol and 4% NaCl prior to 
induction with 0.4 mM IPTG. Finally, we checked protein expression over the investigated 
time course of expression by SDS-PAGE and staining with Coomassie Brilliant Blue. 
 
Figure 17: Test expression of recombinant flagellin from S. typhimurium under salt stress conditions: 
Samples were collected at indicated timepoints of expression (Lanes before salt–5h) and also samples 
representing the solubly expressed (Lane Sol.) and the insolubly expressed (Lane Insol.) protein fractions were 
collected. All samples were separated by SDS-PAGE (15%) and stained with Coomassie Brilliant Blue. Lane M: 
Fermentas 8-16% Tris-glycerine SDS-PAGE marker 
 
The results in Figure 10 indicate that protein expression under salt stress did not sufficiently 
decrease the amount of undesired expressed proteins. Again, prominent bands with 
approximately 37 kDa were detected over the investigated time period (Lanes before salt – 
5h) but neither in the solubly (Lane Sol.) nor in the insolubly (Lane Insol.) expressed protein 
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fractions. In addition, a protein of the expected size of 49.9 kDa was detected (Lanes before 
salt – 5h). The expression of this protein was slightly increased after induction with IPTG 
(Lanes 2h and 5h) compared to the uninduced state (Lane 0). This protein seemed to be 
expressed in inclusion bodies, as it was only detectable in the insolubly expressed (Lane 
Insol.) protein fraction. 
As compared to expression under standard conditions (Fig.15), expression under salt stress 
resulted in a decreased expression of proteins with a higher molecular weight. 
7.5.3 Test expression of flagellin from S. typhimurium at 16°C 
Protein expression at lower temperatures decreases the rate of protein expression. This 
decreased rate of protein synthesis results in an enhanced capacity to fold proteins correctly.  
We induced protein expression by addition of 0.4 mM IPTG and incubated the cells at 16°C 
as E. coli cells still grow and express proteins at this temperature. Finally, we checked protein 
expression over the investigated time course of expression by SDS-PAGE and staining with 
Coomassie Brilliant Blue. 
 
Figure 18: Test expression of recombinant flagellin from S. typhimurium at 16°C: Samples were collected 
before induction and after different timepoints of expression (Lanes Unind.–18h). Samples representing the 
solubly expressed (Lane Sol.) and the insolubly expressed (Lane Insol.) protein fractions were collected too. All 
samples were separated by SDS-PAGE (15%) and stained with Coomassie Brilliant Blue. Lane M: Fermentas 8-
16% Tris-glycerine SDS-PAGE marker 
 
Figure 18 shows a high number of bands in all lanes. The expression of some proteins only 
slightly increased over time. A band indicating a protein of a molecular weight of 49.9 kDa 
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was detected (Lanes Unind. to 18h). However, the expression of this protein (Lanes 4h to 
18h) did not increase compared to the uninduced sample (Lane Unind.). The protein was 
detected in the solubly expressed (Lane Sol.) and in the insolubly expressed (Lane Insol.) 
protein fraction. The most prominent bands appeared in the soluble protein fraction at a size 
of 26 and 30 kDa (Lane Sol.). 
 
As neither expression under salt stress nor expression at 16°C led to improved expression of 
the flagellin protein we decided to skip Immunoblotting and continue with a large scale 
protein expression under standard conditions to purify the protein. 
7.5.4 Large scale expression of flagellin from S. typhimurium and protein 
purification by immobilized metal-ion affinity chromatography 
Protein expression was performed under standard conditions in 1000 mL of culture and His-
tagged proteins were purified by immobilized metal-ion affinity chromatography (IMAC) 
which is based on the covalent binding of amino acids to metals. In our case the expressed 
flagellin carried a histidine-tag. Therefore, we used GE Healthcare His-Trap FF crude 1mL 
columns where the histidine residues are bound to nickel during the loading step. Thereafter, 
bound proteins can be eluted by an increasing gradient of elution buffer containing imidazole. 
Imidazole competes with His-tagged proteins for nickel binding. 
   
Figure 19: Purification of the recombinant flagellin protein by IMAC: Samples (Lanes 1-18 and Lanes 19-
52) were separated by SDS-PAGE (15%) and stained with Coomassie Brilliant Blue Lanes 1-12: flow-through 
Lane M: Fermentas 8-16% SDS marker 
 
Figure 19 shows that protein purification by IMAC did not lead to purification of a protein of 
the expected size of approximately 50 kDa. Instead, one prominent band at a size of around 
26 kDa was detected in the fractions 17, 18, 19 and 20. These fractions also contained smaller 
proteins that might result from degradation of the protein. Bands around 50 kDa were found 
in fractions 1, 6 and 12 indicating that the sample contained a protein of the expected size but 
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either in too small amounts to be detectable after purification or the protein did not bind to the 
column and could therefore not be purified. 
7.6 Testing the ability of E. coli lysates to activate TLR5  
Although the purification of recombinant flagellin from E.coli BL21(DE3)pLysS cells did not 
work, we tested crude bacterial lysates of cells that had been transformed with the vector 
containing the flagellin insert for their ability to activate HEK-293/TLR5 cells. HEK-
293/TLR5 cells respond to stimulation with flagellin by production of IL-8. The cytokine 
concentration was determined by ELISA. 
Standard protein expression was performed as described. The solubly expressed protein 
fraction was used for stimulation of HEK-293/TLR5 cells. “Empty” E.coli BL21(DE3)pLysS 
cells transformed with a pETBlue-2 vector without insert served as a control. Purchased 
flagellin (Invitrogen GmbH) served as a positive control and LPS was used as a negative 
control. 
HEK-293/TLR5 IL-8 ELISA
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Figure 20: IL-8 production of HEK-293/TLR5 cells in response to E.coli lysates: HEK-293/TLR5 cells were 
seeded in a flatbottomed 96 well plate (40000 cells/well) and incubated for 24 hours. Medium was removed and 
replaced by medium containing specific stimuli (medium, LPS: hatched bars; purchased flagellin: grey bars; 
different concentrations of lysate of bacteria transformed with vector containing flagellin: black bars; control 
lysates of bacteria transformed with the vector alone: white bars). After 20 hours IL-8 levels in the supernatants 
were determined by ELISA. 
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Figure 20 shows that neither medium alone nor stimulation with LPS, a TLR4 ligand (hatched 
bars) induced IL-8 production of HEK-293/TLR5 cells. Stimulation with different 
concentrations of recombinant flagellin (grey bars) resulted in IL-8  synthesis in a dose 
dependent manner. The lysate of bacteria containing the vector with the flagellin insert (filled 
bars) induced strong IL-8 production after stimulation of HEK-293/TLR5 cells whereas the 
control lysate from bacteria containing an empty vector (empty bars) did not. We concluded 
that flagellin was expressed and had the capacity to trigger TLR5 stimulation. The levels of 
the expressed protein were possibly too low to allow purification of the protein by IMAC. 
7.7 Amplification of DNA encoding the C- or N-terminal fragments 
of flagellin from S. typhimurium and cloning into pHis parallel 2 
vector 
As our attempts did not lead to successful high level expression of the full-length flagellin 
protein we decided to individually express the conserved regions of the protein. For this 
purpose we cloned the flagellin C-terminus as well as the flagellin N-terminus into the pHis 
parallel 2 vector and separately expressed both proteins in E.coli BL21(DE3)pLysS cells. 
The DNA coding for the N- or the C-terminal fragment of the flagellin protein, which was 
synthetically produced, was used as a template for amplification by PCR.  
Primers were designed including restriction sites for NcoI and XhoI: 
 
Primers: 
Flag C forward: TATACCATGGGAACCGAAAACCCGCTGCAGAAA 
 
Flag C reverse: TATACTCGAGTTAACGCAGTAAAGAGAGGACG 
 
Sequences homologous to the C-terminal fragment of the flagellin protein DNA sequence are 
underlined and sites for enzymatic digest with restriction enzymes are indicated in bold. 
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Flag N forward: TATACCATGGCTCTGGGCACCGCTATCGA 
 
Flag N reverse: TATACTCGAGTTATTGCACATTCAGCGTATCCAGACC 
 
Sequences homologous to the N-terminal fragment of the flagellin protein DNA sequence are 
underlined and sites for enzymatic digestion with restriction enzymes are indicated in bold.  
 
The C-terminal sequence (277bp; bp 1209 – 1485 in the full-length sequence of flagellin, 
Accession No.: M11332) of the flagellin protein from S.typhimurium: 
 
gaccgaaaa cccgctgcag aaaattgatg ctgctttggc acaggttgac 
acgttacgtt ctgacctggg tgcggtacag aaccgtttca actccgctat taccaacctg 
ggcaacaccg taaacaacct gacttctgcc cgtagccgta tcgaagattc cgactacgcg 
accgaagttt ccaacatgtc tcgcgcgcag attctgcagc aggccggtac ctccgttctg 
gcgcaggcga accaggttcc gcaaaacgtc ctctctttac tgcgttaa 
 
The N-terminal Sequence (458bp; bp 83 – 540 in the full-length sequence of flagellin, 
Accession No.: M11332) of the flagellin protein from S.typhimurium: 
 
ctctgggcac cgctatcgag cgtctgtctt ccggtctgcg tatcaacagc 
gcgaaagacg atgcggcagg tcaggcgatt gctaaccgtt ttaccgcgaa catcaaaggt 
ctgactcagg cttcccgtaa cgctaacgac ggtatctcca ttgcgcagac cactgaaggc 
gcgctgaacg aaatcaacaa caacctgcag cgtgtgcgtg aactggcggt tcagtctgct 
aacagcacca actcccagtc tgacctcgac tccatccagg ctgaaatcac ccagcgcctg 
aacgaaatcg accgtgtatc cggccagact cagttcaacg gcgtgaaagt cctggcgcag 
gacaacaccc tgaccatcca ggttggtgcc aacgacggtg aaactatcga tatcgatctg 
aagcagatca actctcagac cctgggtctg gatacgctga atgtgcaa 
 
PCR-amplified products were checked on a 1% (w/v) agarose gel containing EtBr and bands 
indicating the DNA fragment of the correct size were excised under UV light. Bands were 
excised from the gel and digested with the restriction enzymes NcoI and XhoI. In parallel, 
the pHis parallel 2 vector was digested with NcoI and XhoI and dephosphorylated with CIAP 
prior to ligation. The vector containing the insert was then transformed in E.coli TOP10 cells. 
Successful ligation was checked by PCR screening of grown colonies. PCR products were 
checked by DNA gel electrophoresis. 
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Figure 21:  Test digestion of vectors containing the C- and N-terminal fragments of flagellin from S. 
typhimurium: The C-terminal (Lanes 1–3) and the N-terminal (Lanes 4–6) DNA samples were separated on a 
1% (w/v) agarose gel containing EtBr. Lane M: gene ruler 100 bp DNA ladder marker 
 
Figure 21 shows that three colonies transformed with the vector containing the C-terminal 
insert (Lanes 1 – 3) were negative as no bands appeared in the expected size of approximately 
300 bp. Lane 4 – 6 show bands of approximately 500 bp indicating that the N-terminal 
fragment of flagellin was ligated successfully into the pHis parallel 2 vector. 
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As no amplified products were found for the C-terminal fragment the colony screening was 
repeated with additional colonies.  
 
Figure 22: Test digestion of the vector containing the C-terminal fragment of flagellin from S. 
typhimurium: Samples (Lanes 1-3) were separated on a 1% (w/v) agarose gel containing EtBr Lane M: gene 
ruler 100 bp DNA ladder marker 
 
Figure 22 shows that two out of three screened colonies carried a vector containing an insert 
of approximately 300 bp (Lanes 2 and 3) indicating that the C-terminal fragment of flagellin 
was successfully ligated into the vector and transformation into E.coli TOP10 cells had 
worked. Sample 1 did not show any bands at the expected size. 
 
All positive clones for the C- and N-terminal fragments of flagellin were sequenced and 
compared to the original sequences by BLAST analysis. Sequence comparison showed that 
the inserts displayed no mutations (data not shown). Subsequently, we continued with the 
expression of the C- and N-terminal fragments of flagellin as proteins. 
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7.8 Protein expression and purification of the C- and N-terminal 
fragments of flagellin from S. typhimurium 
As a first step, E.coli BL21(DE3)pLysS cells were transformed with the vectors carrying the 
C- or the N-terminal fragment of flagellin, respectively. After transformation, a protein test 
expression was performed. 
7.8.1 Test expression of the C-terminal fragment of flagellin from S. 
typhimurium 
 
Figure 23: Test expression of the C-terminal fragment of flagellin from S. typhimurium: Samples collected 
over the timecourse of expression (Lanes 0-6h) and samples containing the solubly expressed protein fraction 
(Lane Sol.) and the insolubly expressed protein fraction (Lane Insol.) were separated by SDS-PAGE (15%) and 
stained with Coomassie Brilliant Blue Lane M: Fermentas 8-16% Tris-glycerine SDS-PAGE marker 
 
Figure 23 shows the expression of a protein in the range of 11 - 17 kDa over the studied time 
period of 6 hours (Lanes 1h to 6h). This expression product perfectly matched a calculated 
size of 13.1 kDa of the C-terminus of flagellin including the His-tag. The amount of the 
expressed protein increased over time. Both, the soluble and the insoluble protein fraction 
contained the protein, even though the major part of the protein seemed to be insolubly 
expressed (Lane Insol.). 
In addition, several bands indicating proteins of higher molecular weight in all lanes were 
visible. However, expression of these proteins did not increase after induction with IPTG. 
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An Immunoblot was performed using a detection system specific for the His-tag to assess, 
whether the massively expressed protein detectable in the Coomassie stained gel indeed was 
the protein of interest. 
 
Figure 24: Immunoblot of the C-terminal fragment of flagellin from S. typhimurium: The same samples 
(Lanes 0–Insol.) as described for Fig.17 were separated by SDS-PAGE (15%) and transferred onto a 
nitrocellulose membrane. After saturation and washing, a Penta-His™ antibody was added. A HRP-linked 
antibody served as a secondary antibody and the Lumigen™ detection reagent was used in combination with a 
hyperfilm to detect proteins carrying the His-tag. Lane M: Fermentas 8-16% Tris-glycerine SDS-PAGE marker 
 
Figure 24 shows His-tagged proteins of around 13.1 kDa in all lanes except for Lane 0 
(uninduced sample). This observation indicated that the C-terminal fragment was not 
expressed in high amounts as long as the lac repressor remained active. Upon induction with 
IPTG the protein was strongly expressed.  Immunoblotting confirmed the result obtained by 
Coomassie staining of the test expression (Fig. 23). However, His-tagged proteins of a 
molecular weight of 23 kDa and 38 kDa (Lanes 3h to 6h and Lane Insol.) were also detected. 
These bands cannot represent dimers or trimers of the C-terminal fragment of flagellin. The 
solubly expressed protein fraction (Lane Sol.) exclusively contained the protein of the 
expected size of 13.1 kDa. 
 
As optimum protein expression was observed after 5 hours (Fig. 23 & Fig.24) a period of 5 
hours was chosen for protein expression of the C-terminal fragment of flagellin. 
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7.8.2 Test expression of the N-terminal fragment of flagellin from S. 
typhimurium 
 
Figure 25: Test expression of the N-terminal fragment of flagellin from S. typhimurium: Samples were 
collected over a time period of 6 hours (Lanes 0-6h) and separated by SDS-PAGE (15%) together with samples 
containing the solubly expressed protein fraction (Lane Sol.) and the insolubly expressed protein fraction (Lane 
Insol.). The gel was stained with Coomassie Brilliant Blue Lane M: Fermentas 8-16% Tris-glycerine SDS-PAGE 
marker 
 
The calculated size for the N-terminal fragment including the His-tag was 18.8 kDa. 
Figure 18 shows a weak band in the range of 20 kDa after 1 to 3h of expression (Lanes 1h to 
3h) which disappeared after longer expression periods (Lanes 4h to 6h) and was also not 
detectable in the soluble (Lane sol.) and insoluble protein fraction (Lane insol.). Additional 
bands around 25 kDa and approximately 40 kDa were visible and seemed to increase in their 
intensity over the timecourse of expression. These bands were also detected in the soluble and 
the insoluble protein fraction (Lane Sol. & Lane Insol.). 
 
To analyse whether the weak bands of approximately 20 kDa represented the protein of 
interest we performed an Immunoblot to specifically detect His-tagged proteins. 
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Figure 26: Immunoblot of the N-terminal fragment of flagellin from S. typhimurium: The same samples 
(Lanes 0–Insol.) as described in Fig.17 except for the 6h sample were separated by SDS-PAGE (15%) and 
transferred onto a nitrocellulose membrane. After saturation and washing a Penta-His™ antibody was added. A 
HRP-linked antibody served as a secondary antibody and the Lumigen™ detection reagent was used in 
combination with a hyperfilm to detect proteins carrying the His-Tag. Lane M: Fermentas 8-16% Tris-glycerine 
SDS-PAGE marker 
 
Figure 26 shows that a protein of approximately 19 kDa (Lanes 1h to 3h) appeared and was 
totally degraded after 3 hours of induction and therefore could not be detected by 
immunoblotting either at later time points (Lanes 4h and 5h) or in the soluble protein fraction 
(Lane Sol.). The insoluble fraction (Lane Insol.) shows a very weak band which is much 
weaker compared to the intense bands in Lanes 2h and 3h. Lanes 2h and 3h also show bands 
of weaker intensity of approximately 30 kDa and also of 72 kDa.  
 
Western Blotting confirmed the results obtained by Coomassie staining. A time period of 2 
hours was chosen to express the N-terminal fragment of flagellin from S. typhimurium. 
 
Thereafter, a large scale protein expression was performed and proteins were purified by 
immobilized metal ion affinity chromatography as described before. 
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7.8.3 Large scale expression of the C- and the N-terminal fragments of 
flagellin from S. typhimurium and protein purification by 
immobilized metal-ion affinity chromatography 
7.8.3.1 Protein purification of the C-terminal fragment of flagellin by IMAC 
  
Figure 27: Purification of the C-terminal fragment of flagellin by IMAC: Samples (Lanes 1-9 and Lanes 10-
18) were separated by SDS-PAGE (15%) and stained with Coomassie Brilliant Blue Lanes 1-3: flow-through 
Lane M: Fermentas 8-16% Tris-glycerine SDS-PAGE marker  
 
Figure 27 shows strong protein expression in different fractions (Lanes 9 to 13) indicating that 
the C-terminal fragment of flagellin with a calculated molecular weight of 13.1 kDa was 
purified by chromatography. The fractions showing the flow-through (Lanes 1 to 3) contained 
no bands at the expected size of 13.1 kDa. This confirms that the protein containing the His-
tag had bound efficiently to the column. The band at 26 kDa (Lanes 5 to 12) presumably 
resulted from a dimer of the protein. Lanes 10 to 13 contained bands at a size of 
approximately 36 kDa that might result from a trimer of the protein. Fractions 14 to 18 
contained no bands which proved that the proteins bound to the column were washed out at 
lower concentrations of imidazole. 
Fractions 9 to 13 were pooled for dialysis of the protein. 
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7.8.3.2 Protein purification of the N-terminal fragment of flagellin by IMAC 
  
Figure 28: Purification of the N-terminal fragment of flagellin by IMAC: Samples (Lanes 1–9) were 
separated by  SDS-PAGE (15%) and stained with Coomassie Brilliant Blue Lanes 1-4: flow-through Lane M: 
Fermentas 8-16% Tris-glycerine SDS-PAGE marker  
 
Figure 28 shows that the N-terminal fragment of flagellin from S. typhimurium was purified 
by IMAC as the Coomassie Brilliant Blue stained SDS-PAGE gels showed intense bands at 
the calculated size of 18.8 kDa in Lanes 9 to 16. Lanes 1 and 2 also contained bands around 
this size possibly resulting from a protein, that had not bound to the column and was directly 
washed out. Some weak bands were detected indicating proteins of a higher molecular weight 
(Lanes 10 to 15) that might result from multimers of the N-terminal fragment of flagellin. 
Lanes 5 to 8 showed only very weak bands indicating that the protein was obviously eluted at 
higher concentrations of imidazole. 
Fractions 10 to 16 were pooled for dialysis. 
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Pooled fractions were dialysed against 1x PBS and then analysed for purity by SDS-PAGE. 
 
Figure 29: Coomassie staining of the dialysed N- and C-terminal fragments of flagellin from S. 
typhimurium: Fractions were pooled after IMAC and dialysed against 1x PBS. Samples (Lanes N and C) were 
separated by SDS-PAGE (15%) and stained with Coomassie Brilliant Blue Lane M: Fermentas 8-16% Tris-
glycerine SDS-PAGE marker 
 
Figure 29 shows that the protein sample for the C-terminal fragment of flagellin was pure as 
only one very intense band at the expected size of approximately 13 kDa (Lane C) was 
detected. The sample for the N-terminal fragment showed a very intense band at the expected 
size of approximately 19 kDa but also several weak bands indicating proteins of a higher 
molecular weight (Lane N). 
To confirm whether the intense bands really reflected the N- and C-terminal flagellin proteins 
we performed an immunoblot to detect His-tagged proteins. 
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Figure 30: Immunoblot of the dialysed N- and C-terminal fragments of flagellin from S. typhimurium: 
Fractions were pooled after IMAC and dialysed against 1x PBS. Samples (Lanes N and C) were separated by 
SDS-PAGE (15%) and transferred onto a nitrocellulose membrane. After saturation and washing, a Penta-His™ 
antibody was added. A HRP-linked antibody served as a secondary antibody and the Lumigen™ detection 
reagent was used in combination with a hyperfilm to detect proteins carrying the His-tag. Lane M: Fermentas 8-
16% Tris-glycerine SDS-PAGE marker 
 
Figure 30 shows that the pooled fractions contained the proteins of interest after dialysis. Lane 
N shows one single band at the expected size of approximately 19 kDa and Lane C shows the 
expected band at the size of approximately 13 kDa. As Lane N does not show any other 
bands, the slight bands in the Coomassie stained gel must have resulted from proteins 
different than the His-tagged N-terminal fragment. 
7.9 Testing the ability of the C- and N-terminal fragments of 
flagellin from S. typhimurium to activate TLR5  
7.9.1 Testing the ability to activate TLR5 on HEK-293/TLR5 cells 
The purified proteins of the C- and N-terminal fragments of flagellin from S. typhimurium 
were tested for their potential to activate TLR5 using HEK-293/TLR5 cells as described 
before. 
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Figure 31: TLR5 activation of the C- and N-terminal fragments of flagellin: HEK-293/TLR5 cells were 
seeded in a flatbottomed 96 well plate (40000 cells/well) and incubated for 24 hours. Medium was removed and 
replaced by medium containing the specific stimuli. After 20 hours IL-8 production was determined by ELISA. 
 
Figure 31 shows that HEK-293/TLR5 cells responded to stimulation with recombinant full-
length flagellin from S. typhimurium in a dose-dependent manner. Neither equimolar amounts 
of the N-terminal fragment and the full-length protein nor the C-terminal fragment and the 
full-length protein resulted in IL-8 synthesis. We conclude that the conserved regions of 
flagellin alone are biologically inactive concerning activation of TLR5. As expected, LPS had 
no effect on IL-8 production of HEK-293/TLR5 cells. 
7.9.2 Testing the ability to activate TLR5 on CaCo-2 cells 
To test the effects of flagellin on different cell types we employed CaCo-2 cells. This 
immortalized cell-line derived from human epithelial colorectal adenocarcinoma cells shows 
the ability to differentiate into small intestinal-like cells after confluent growth. We were 
interested in the effects of flagellin stimulation of these cells as they could function as a 
model system for intestinal functions.  
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Figure 32: Stimulation of CaCo-2 cells with the C- and N-terminal fragments of flagellin: CaCo-2 cells 
were seeded in a flatbottomed 96 well plate (40000 cells/well) and incubated for 24 hours. Medium was removed 
and replaced by medium containing the specific stimuli. After 22 hours IL-8 production was determined by 
ELISA. 
 
Figure 32 shows that stimulation of CaCo-2 cells with recombinant flagellin of S. 
typhimurium resulted in the secretion of IL-8 in a dose-dependent manner whereas neither the 
C-terminal nor the N-terminal fragment alone triggered IL-8 secretion. CaCo-2 cells did not 
respond to stimulation with LPS. 
 
These results showed that HEK-293 cells stably transfected with TLR5 as well as CaCo-2 
cells responded to stimulation with recombinant flagellin of S. typhimurium with IL-8 
secretion. HEK-293/TLR5 cells produced higher amounts of IL-8 compared to CaCo-2 cells. 
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7.10 Amplification and cloning of DNA encoding a fusion protein of 
the N- and C-terminal fragments of flagellin from S. 
typhimurium linked by the hinge-region of the E.coli MukB 
protein into pHis parallel 2 vector 
 
As neither the N- nor the C-terminal fragment of flagellin separately bound to TLR5 and 
induced IL-8 secretion, we linked the N- and C-termini with a hinge region of E.coli that has 
previously been shown to bring amino acid carboxyl protein regions into hairpin stem 
structures [41]. For this purpose, new primers were designed to clone the hinge region in 
between the N- and the C-terminal fragments of flagellin (Fig. 33). 
 
E.coli MukB hinge region(bp 1996 – 2349 of NCBI Accession No.:NC_009801) 
ccagg tggttctgaa gatcagcgtc tgaacgcgct ggcggagcgt 
tttggtggtg tgctgctgtc agaaatttat gacgacgtta gcctggaaga tgcgccgtac 
ttctcagcac tgtatggccc gtcacgccac gccatcgtgg tgccagatct gtcacaggta 
accgaacacc tggaaggctt gaccgattgc ccggaagatc tctatttgat cgaaggggat 
ccgcagtcat tcgatgacag cgtgttcagc gttgatgagc tggaaaaagc ggtggtggtg 
aaaatcgccg atcgtcagtg gcgttattca cgtttcccgg aagtgccgct gtttggtcgt 
gctgcgcgt 
 
 
Figure 33: Cloning scheme for the hinge region of E.coli MukB in between the N- and C-terminal 
fragments of flagellin from S. typhimurium 
 
Primers: 
Flag N forward NcoI: TATACCATGGCTCTGGGCACCGCTATCGA 
 
Flag N reverse EcoR1: TATAGAATTCCTTGCACATTCAGCGTATCCAGAC 
 
Flag C forward Sal1: TATAGTCGACCGAAAACCCGCTGCAGAAAA 
 
Flag C reverse Not1: TATAGCGGCCGCTTAACGCAGTAAAGAGAGGACG 
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Hinge forward EcoR1: TATAGAATTCCAGGTGGTTCTGAAGATCAGC 
 
Hinge reverse Sal1: TATAGTCGACGTACGCGCAGCACGACCAAACAG 
 
Sequences homologous to the DNA sequence are underlined and sites for enzymatic digest 
with restriction enzymes are indicated in bold.  
 
The cloning procedure was performed as described for the N- and C-terminal fragment of 
flagellin. As a first step the N-terminal fragment of flagellin was cloned into the pHis parallel 
2 vector. Next, the hinge-region was cloned into the vector. Finally, the C terminal fragment 
was cloned into the vector already containing the other two fragments. The complete 
construct was used for transformation of E.coli BL21(DE3)pLysS cells.  
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7.11 Protein expression and purification of the fusion construct of 
the N- and C-terminal fragments of flagellin from S. 
typhimurium linked with the hinge-region of E.coli MukB 
protein  
7.11.1 Test expression of the fusion protein 
Protein expression was performed under standard conditions as described before. 
 
Figure 34: Test expression of the N-terminal fragment – hinge region – C-terminal fragment construct: 
Samples were collected over the timecourse of expression (Lanes 0–6h) and separated by SDS-PAGE (15%) 
together with samples containing the solubly expressed protein fraction (Lane Sol.) and the insolubly expressed 
protein fraction (Lane Insol.).The gel was stained with Coomassie Brilliant Blue Lane M: Fermentas 8-16% Tris-
glycerine SDS-PAGE marker 
 
Figure 28 shows increased expression of a protein with a molecular weight of approximately 
45 kDa over time upon induction with IPTG (Lanes 1h-5h). This protein was found mainly in 
the insolubly expressed protein fraction (Lane Insol.) but was also detected in the solubly 
expressed protein fraction (Lane Sol.). The calculated size for the construct is 42.79 kDa 
corresponding to the visible bands of around 45 kDa. A slight increase in expression of a 
protein of approximately 72 kDa (Lanes 1h-5h) was also observed. 
 
As a next step we performed an Immunoblot of the solubly and the insolubly expressed 
protein fractions to check whether these fractions indeed contained the His-tagged protein of 
interest. 
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Figure 35: Immunoblot of the expression of the N-terminal fragment – hinge region – C-terminal 
fragment construct: Samples of the solubly (Lane Sol.) and the insolubly (Lane Insol.) expressed protein 
fractions were separated by SDS-PAGE (15%) and transferred onto a nitrocellulose membrane. After saturation 
and washing, a Penta-His™ antibody was added. A HRP-linked antibody served as a secondary antibody and the 
Lumigen™ detection reagent was used in combination with a hyperfilm to detect proteins carrying the His-tag. 
Lane M: Fermentas 8-16% Tris-glycerine SDS-PAGE marker 
 
Figure 35 shows that a protein of approximately 45 kDa was expressed in both, the soluble 
and the insoluble protein fraction (Lanes Sol.&Insol.). Both lanes also contained a His-tagged 
protein with a molecular weight of 34 kDa that might result from degradation.  
Next, a large scale protein expression of the soluble protein fraction was performed and the 
protein was purified by IMAC. 
7.11.2 Purification of the fusion protein by IMAC 
Protein purification was done as described above. 
  
Figure 36:  Purification of the N-terminal fragment - hinge region - C-terminal fragment fusion protein by 
IMAC: Samples (Lanes 1-9 and Lanes 10-18) were separated by SDS-PAGE (15%) and stained with Coomassie 
Brilliant Blue Lane M: Fermentas 8-16% Tris-glycerine SDS-PAGE marker  
 
Figure 36 shows lots of bands in the flow-through fractions (Lanes 1&2) but both fractions 
did not show very intense bands at the size of approximately 45 kDa corresponding to the 
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His-tagged protein. Fractions 3 to 5 did not show any bands indicating that the amount of 
imidazole was too low to elute bound proteins from the column. Fractions 6 to 10 showed 
several bands including a band of 45 kDa indicating that the eluted His-tagged protein was 
rather impure as several bands were visible in these fractions. The smaller bands might result 
from degradation of the fusion protein, but there were also bands of 72 kDa that could not 
result from dimers or trimers of the protein. Fractions 11 to 15 showed more intense bands of 
45 kDa indicating that the protein of interest was mainly contained in these fractions. 
However, there were also several smaller bands presumably resulting from degradation and 
also one band at 72 kDa. The protein could not be purely eluted. Fractions 16 to 18 showed 
decreased concentrations of the protein at 45 kDa and no additional bands indicating that all 
bound sample was already eluted at lower concentrations of imidazole. 
 
Fractions 11 to 16 were pooled and dialysed against 1x PBS. The dialysed protein was used to 
assess, whether the N-terminal fragment – hinge region – C-terminal fragment fusion protein 
could activate TLR5. 
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7.12 Testing the ability of the N-terminal fragment – hinge region – 
C-terminal fragment fusion protein to activate TLR5  
To test the biological activity of the fusion protein, HEK cells stably transfected with TLR5 
were stimulated and IL-8 secretion was determined by ELISA as described above. 
HEK-293/TLR5  IL-8 ELISA
0,0
1000,0
2000,0
3000,0
4000,0
5000,0
6000,0
7000,0
8000,0
M
ed
iu
m
LP
S
rF
la
ge
lli
n 
[5
0 
ng
/m
L]
rF
la
ge
lli
n 
[1
0 
ng
/m
L]
rF
la
ge
lli
n 
[2
 n
g/
m
L]
N
H
in
ge
C
 [5
0 
ng
/m
L)
N
H
in
ge
C
 [1
0 
ng
/m
L)
N
H
in
ge
C
 [2
 n
g/
m
L)
N
H
in
ge
C
 [1
 n
g/
m
L)
N
H
in
ge
C
 [0
.5
 n
g/
m
L)
IL
-8
 [
p
g
/m
l]
 
Figure 37: TLR5 activation of the N-terminal fragment – hinge region – C-terminal fragment fusion 
protein: HEK-293/TLR5 cells were seeded in a flatbottomed 96 well plate (40000 cells/well) and incubated for 
24 hours. Medium was removed and replaced by medium containing the specific stimuli (medium: dotted bar; 
LPS: hatched bar; different concentrations of recombinant flagellin: full bars; different concentrations of the 
fusion protein: empty bars). After 20 hours IL-8 production was determined by ELISA. 
 
Figure 37 shows that recombinant flagellin (full bars) induced IL-8 secretion in a dose 
dependent manner after stimulation of HEK-293/TLR5 cells whereas LPS stimulation 
(hatched bar) did not. Stimulating cells with the N-terminal fragment – hinge region – C-
terminal fragment construct (empty bars) also induced IL-8 synthesis by HEK-293/TLR5 cells 
indicating that the protein was biologically active concerning TLR5 activation. 
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8 Discussion 
TLR ligands are becoming more important in the field of allergy because they may be 
potential adjuvants for allergy vaccines. Clinical trials with TLR4 and TLR9 ligands have 
already shown promising results [26, 31]. The TLR2 ligand Pam3Csk4 was shown to induce 
TH1-type T-cell responses and regulatory T-cells [26]. A monophosphoryl lipid A-adjuvanted 
vaccine was shown to reduce seasonal allergen-specific IgE boosts and led to the induction of 
allergen-specific IgG blocking antibodies [31]. To find out whether flagellin, a TLR5 ligand, 
could also be a potential adjuvant candidate for allergy vaccines flagellin-induced production 
of key cytokines in PBMC from allergic patients was analysed. Stimulation of PBMC from 
birch-pollen allergic patients with commercially available flagellin from S. typhimurium 
induced the immunosuppressive cytokine IL-10 (Fig. 2, Fig. 3) and a weak production of the 
TH1-type cytokine IFN-γ (Fig. 4, Fig. 5) but no TNF-α (data not shown). These preliminary 
results indicated that flagellin might be a potential adjuvant for allergy vaccination. The major 
aim of this diploma thesis was to produce high amounts of recombinant flagellin in order to 
confirm this hypothesis. 
 
First, we established a read-out system for TLR5 triggering. For this purpose, HEK-293 cells 
stably transfected with TLR5 (HEK-293/TLR5 cells) and CaCo-2 cells were stimulated with 
commercially available recombinant flagellin from S. typhimurium. HEK-293/TLR5 
responded with IL-8 synthesis in a dose-dependent manner (Fig. 6). LPS stimulation did not 
lead to IL-8 production indicating that contamination of the flagellin protein with endotoxins 
did not affect the results (Fig. 6). Stimulation of CaCo-2 cells with flagellin resulted in lower 
IL-8 synthesis as compared to HEK-293/TLR5 cells (Fig. 7). In parallel, we investigated 
whether heat-labile serological factors were important for the ability of flagellin to trigger 
TLR5 responses. We usually supplemented our cell-culture media with FCS that was heat-
inactivated, which is not a physiologic condition. With regard to possible allergy vaccines we 
wanted to ensure that heat-labile serological factors could not influence the biological activity. 
For this purpose, HEK-293/TLR5 cells were stimulated with recombinant flagellin in the 
presence of FCS that was either heat-inactivated or not. IL-8 secretion did not differ between 
both groups (Fig. 8). There was slightly increased IL-8 production in the presence of heat-
labile serological factors when stimulated with high doses of flagellin but this effect was 
diminished when lower flagellin concentrations were applied (Fig. 8). This observation 
indicated that heat-labile serological factors had no influence on the effects of TLR5 
activation. 
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Based on these findings, we decided to use HEK-293/TLR5 as a read-out system for the 
ability of a TLR5 ligand to trigger TLR5 responses. Moreover, HEK-293/TLR5 cells could be 
detached easier compared to CaCo-2 cells and CaCo-2 cells appeared to be more sensitive to 
stress as they showed a decreased growth rate after splitting of cells.  
 
We amplified the DNA coding for flagellin and transformed bacterial cells with a vector 
containing the gene of interest. Next, we tried to express the full length flagellin under 
different conditions including salt stress or low-temperature (Fig.15, Fig.17 and Fig. 18). 
Unfortunately, none of these approaches resulted in a satisfactory expression of flagellin. 
Nevertheless, we tried protein purification by IMAC but were not able to purify detectable 
amounts of the protein (Fig. 19). Interestingly, stimulation of HEK-293/TLR5 cells with a cell 
lysate of E. coli cells containing the vector with the flagellin insert resulted in IL-8 synthesis 
(Fig. 20). Therefore, we conclude that the flagellin protein was expressed in a biological 
active form. However, we could not purify it by IMAC nor clearly detect it either by 
Coomassie Brilliant Blue staining or by Immunoblotting applying a detection system specific 
for His-tagged proteins. Probably the E.coli BL21(DE3)pLysS strain was not able to express 
sufficient amounts of the protein for detection or the protein was degraded. It could also be 
possible that the His-tag of the protein was not accessible for purification by IMAC and 
detection with His-tag-specific antibodies. 
  
Recognition by TLR5 is accomplished by binding of certain conserved amino acids in the D1 
region (Fig. 1) [35, 36]. The D0 and the D1 region are mainly formed by structures encoded 
in the N- and C-terminal parts of the flagellin protein. Since we had problems with expression 
of the full length protein, the next step was to express the N- and C-terminal fragments of 
flagellin as individual proteins. Both fragments could be cloned and expressed in E.coli cells 
(Fig. 23 - 26) and purified by IMAC (Fig.27 - 30). The successful expression of both, the N- 
and C-terminal fragments indicated that the E.coli BL21(DE3)pLysS strain could not 
correctly express the D2 and D3 regions of the flagellin protein, that are formed by structures 
encoded in the central region of the protein. Testing both flagellin fragments for TLR5 
triggering using HEK-293/TLR5 cells revealed that neither the N- or C-terminal fragments 
alone nor a mixture of both fragments induced the synthesis of IL-8 (Fig. 31). We also tested 
the two fragments on CaCo-2 cells for binding and activating TLR5. Again, no detectable IL-
8 synthesis was observed (Fig. 32). We concluded that the individual N- and C-terminal 
fragments encoded by the conserved DNA sequences of the flagellin protein were not capable 
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of activating TLR5. This might be due to incorrect folding of the proteins so that TLR5 is not 
able to recognize the structure. We speculated that the N- and C-terminal fragments of 
flagellin have to be brought into close proximity in order to trigger TLR5.  
 
It has previously been reported that the hinge region of the MukB protein of E.coli could be 
used to bring the N- and the C-terminal fragments of flagellin into close proximity [42]. 
Therefore, we engineered a fusion protein consisting of the N- and C-terminal fragments of 
flagellin and this hinge region. The resulting fusion protein had a calculated molecular weight 
of approximately 43 kDa and therefore, was slightly smaller than the full-length flagellin 
protein with a calculated molecular weight of 49.9 kDa. We were able to express and purify 
the fusion protein indicating that the E.coli BL21(DE3)pLysS strain was able to express 
sufficient amounts of this artificial construct whereas the full-length S. typhimurium protein 
could not be expressed. Maybe the slight differences in the molecular weight of the proteins 
were critical in their expression or species related factors were of importance. 
Stimulation of HEK-293/TLR5 cells with the fusion protein resulted in the synthesis of IL-8 
demonstrating that linking the N- and C-terminal fragments with the hinge region of the 
MukB protein from E. coli resulted in a fusion protein recognized by TLR5. The hinge region 
has previously been shown to induce hairpin stem structures in amino acid carboxyl protein 
regions [41]. Maybe this function was important to express the protein in the E.coli 
BL21(DE3)pLysS strain and to recover the biological activity of the fragments. 
 
In this diploma thesis we established a model read-out system for TLR5 activation and 
attempted to express the TLR5 ligand flagellin from S. typhimurium in E. coli cells. We were 
not able to express the full-length protein but the N- and C-terminal fragments of flagellin, 
which form the conserved parts of the protein. As the individual fragments did not trigger 
TLR5 we created a fusion construct including a hinge region of the MukB protein from E. 
coli. This approach restored the ability to bind and activate TLR5. We are now able to 
produce large amounts of this fusion protein to assess, if such a protein may serve as an 
adjuvant in allergy vaccines.  
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9.3 Zusammenfassung 
Liganden für Toll-like Rezeptoren (TLR) werden als mögliche Adjuvantien in Impfstoffen für 
die allergen-spezifische Immuntherapie diskutiert. So konnte beispielsweise gezeigt werden, 
dass die Beimengung von DNA, die CpG-Motive enthält und von TLR9 erkannt wird, zu 
Allergieimpfstoffen die allergische Immunantwort gegen-regulieren kann. In dieser 
Diplomarbeit wurde untersucht, ob das bakterielle Protein Flagellin, welches von TLR5 
erkannt wird, ebenfalls immunmodulierende Eigenschaften aufweist. In weiterer Folge sollte 
Flagellin von Salmonella typhimurium als rekombinantes Protein hergestellt werden. 
Zunächst wurden periphere mononukleäre Blutzellen (PBMC) von Birkenpollenallergikern 
mit Flagellin von S. typhimurium stimuliert. Die darauf folgende Zytokinantwort wurde 
mittels ELISA analysiert. Es wurde die Produktion von IFN-γ sowie IL-10 festgestellt, was 
darauf hindeutete, dass Flagellin als Adjuvans wirksam sein könnte. Als nächsten Schritt 
etablierten wir ein Testmodell, um eine Aktivierung über TLR5 rasch nachzuweisen. Dieses 
Modell basierte einerseits auf der Verwendung von humanen embryonalen Nierenzellen 
(human embryonic kidney cells, HEK cells), die mit TLR5 stabil transfiziert worden waren 
und andererseits auf der Stimulation von CaCo-2 Zellen. Parallel dazu wurde die Wichtigkeit 
der Präsenz von hitzelabilen Serumfaktoren für die Aktivierung über TLR5 untersucht. Die 
Resultate bei Verwendung von kommerziell erhältlichem Flagellin von S. typhimurium 
zeigten, dass HEK-293/TLR5 Zellen bei Beimengung von fötalem Kälberserum (10%) zum 
Nährmedium bestens geeignet waren, die Aktivierung über TLR5 nachzuweisen. 
Wir versuchten, Flagellin von S. typhimurium in einen geeigneten Vektor zu klonieren und 
das Protein in E. coli BL21(DE3)pLysS Zellen zu exprimieren. Da mehrere Versuche, das 
Gesamtprotein rekombinant herzustellen, scheiterten, haben wir uns auf die Herstellung der 
C- und N-terminalen Fragmente des Proteins konzentriert. Diese konservierten Bereiche sind 
wesentlich an der Bildung der D0 und D1 Domänen von Flagellin beteiligt, die von TLR5 
gebunden werden. Wir konnten sowohl das C- als auch das N-terminale Protein in E. coli 
BL21(DE3)pLysS Zellen exprimieren und mittels chromatographischer Methoden reinigen, 
jedoch konnten weder die einzelnen Fragmente, noch eine Mischung beider Proteine, TLR5 
aktivieren. Daraufhin wurde ein Fusionsprotein, in dem die C- und N-terminalen Fragmente 
von Flagellin aus S. typhimurium mit einer Gelenksregion aus einem E. coli Protein verknüpft 
wurden, hergestellt. Dieses Fusionsprotein konnte exprimiert und gereinigt werden und erste 
Tests auf HEK-293/TLR5 Zellen führten zu IL-8 Produktion. Dies zeigte, dass die C- und N-
terminalen Fragmente verknüpft und in räumliche Nähe gebracht werden müssen, um TLR5 
zu aktivieren. 
 92 
Zusammenfassend weisen mehrere Ergebnisse, aus Versuchen mit Zellen von Allergikern, 
darauf hin, dass Flagellin immunmodulatorische Eigenschaften aufweist. Es wurde ein 
Testmodell für den Nachweis einer Aktivierung von TLR5 etabliert und ein rekombinantes 
Fusionsprotein hergestellt, das aus den hochkonservierten N- und C-terminalen Fragmenten 
von Flagellin aus S. typhimurium sowie einer Gelenksregion aus E. coli besteht. Dieses 
Fusionsprotein konnte TLR5 aktivieren. 
In nächster Zukunft ist geplant, dieses Fusionsprotein in ausreichender Menge endotoxinfrei 
herzustellen und hinsichtlich seiner immunmodulatorischen Effekte auf PBMC von 
Allergikern zu testen. 
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